TL;DR: Tesamorelin (brand name Egrifta; also designated TH9507) is a stabilized synthetic analog of endogenous growth hormone-releasing hormone (GHRH). Unlike most GHRH analogs studied in research contexts, tesamorelin is an FDA-approved prescription medication, indicated specifically for the reduction of excess visceral abdominal fat in HIV-infected adults with HIV-associated lipodystrophy. Phase-3 clinical trial evidence (n>800) documents ~15–18% visceral adipose tissue (VAT) reduction at 26 weeks. Its mechanism operates via GHRH receptor agonism → pulsatile GH secretion → IGF-1 axis activation. It is a prescription-only medicine; this article is educational mechanism and evidence science only.

Important Compliance Note: This article is for educational and research reference purposes only. Tesamorelin (Egrifta) is an FDA-approved prescription medication indicated for one specific condition: reduction of excess visceral abdominal fat in HIV-infected adults with HIV-associated lipodystrophy. This content does not provide medical advice, does not describe how to obtain or use this medication, does not address off-label use, and does not constitute a dosing protocol. Only a licensed physician can prescribe tesamorelin and assess its appropriateness for any individual. For adults 21+ with a research interest only.

What Is Tesamorelin? Definition and Classification

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the anterior pituitary to release growth hormone (GH). Its full chemical designation is trans-3-hexenoic acid-GHRH(1-44)-NH₂, sometimes written as TH9507. Whereas native GHRH(1-44) degrades rapidly in plasma, with a half-life measured in minutes, tesamorelin incorporates a trans-3-hexenoic acid modification at the N-terminus that confers resistance to dipeptidyl peptidase-4 (DPP-4) cleavage, extending its biological activity.

Tesamorelin is marketed under the brand name Egrifta (and subsequently Egrifta SV, a more concentrated formulation) by Theratechnologies Inc. It holds FDA approval granted in November 2010 for a single, specific indication: reduction of excess visceral abdominal fat in HIV-infected adults with lipodystrophy. This is a narrowly defined regulatory approval, it does not extend to general body composition, anti-aging, athletic performance, or any other indication.

How Does Tesamorelin Work? The GHRH Receptor Mechanism

What is the GHRH receptor pathway?

Tesamorelin exerts its primary biological effect by binding and activating the GHRH receptor (GHRHR) expressed on somatotroph cells of the anterior pituitary gland. GHRHR is a G-protein–coupled receptor; agonist binding triggers adenylyl cyclase activation, cyclic AMP accumulation, and downstream protein kinase A signaling that culminates in the synthesis and pulsatile secretion of growth hormone (GH) from somatotrophs.

Critically, tesamorelin stimulates pulsatile GH secretion, preserving the physiological rhythm of GH release, rather than producing the sustained, non-pulsatile GH elevations associated with exogenous recombinant human GH (rhGH) injection. This distinction is pharmacologically important: pulsatile GH patterns are associated with differential tissue effects compared to continuous GH exposure, including more selective lipolytic activity in visceral adipose tissue.

How does GH activation lead to visceral fat reduction?

Growth hormone stimulates lipolysis (the breakdown of stored triglycerides) in adipose tissue via hormone-sensitive lipase (HSL) activation. Visceral adipose tissue (VAT), the metabolically active fat depot surrounding abdominal organs, is particularly responsive to GH-mediated lipolysis due to its high density of GH receptors and active lipid turnover compared to subcutaneous adipose tissue. Tesamorelin’s GH-stimulating mechanism therefore has a preferential effect on VAT reduction.

GH secretion additionally drives hepatic and peripheral production of insulin-like growth factor 1 (IGF-1). In the phase-3 clinical trials reviewed below, tesamorelin treatment produced a mean IGF-1 increase of approximately 81–108% versus baseline, consistent with robust GH axis activation. IGF-1 elevation is a standard pharmacodynamic marker used to confirm GHRH analog activity in clinical studies.

Why does tesamorelin spare subcutaneous fat?

A consistent finding across tesamorelin’s clinical trial program is that VAT decreases significantly while subcutaneous adipose tissue (SAT) does not decrease, and in some analyses shows no statistically significant change. The mechanistic basis appears to relate to depot-specific differences in adrenergic receptor density, GH receptor expression, and the relative rate of lipolytic responsiveness. The clinical implication is that tesamorelin’s effects are selectively targeted to the abdominal visceral compartment, which is the therapeutically relevant depot in HIV-associated lipodystrophy.

What Is HIV-Associated Lipodystrophy? The Clinical Context

HIV-associated lipodystrophy is a metabolic complication documented in HIV-infected individuals receiving antiretroviral therapy (ART), particularly older protease-inhibitor–based regimens. It is characterized by disproportionate visceral fat accumulation in the abdomen, sometimes accompanied by peripheral fat wasting (lipoatrophy) from the face, limbs, and buttocks. The condition is associated with an unfavorable cardiometabolic risk profile, elevated triglycerides, dyslipidemia, and insulin resistance, and significant patient-reported body image distress.

Prior to tesamorelin’s approval, treatment options for the visceral fat component were limited. Recombinant human GH (rhGH) could reduce VAT but was associated with insulin resistance, arthralgias, edema, and other adverse effects at the doses required. Tesamorelin’s GHRH mechanism, which works through the body’s own pituitary-regulated GH pulse architecture, was hypothesized to produce targeted VAT reduction with a more favorable safety profile, a hypothesis the phase-3 trial program addressed directly.

What Does the Phase-3 Clinical Trial Evidence Show?

The landmark NEJM trial: Falutz et al. 2007

The foundational tesamorelin trial enrolled 412 HIV-infected patients with excess abdominal fat accumulation in a multicenter, randomized, double-blind, placebo-controlled design. Patients received either subcutaneous tesamorelin 2 mg/day or placebo for 26 weeks. The primary endpoint was percent change in visceral adipose tissue by CT scan. According to PubMed, the results published by Falutz et al. in The New England Journal of Medicine (2007; PMID 18057338) showed:

• VAT decreased by 15.2% in the tesamorelin group versus an increase of 5.0% in the placebo group (P<0.001)
• Triglycerides decreased by 50 mg/dL (tesamorelin) versus increased by 9 mg/dL (placebo) (P<0.001)
• Total cholesterol-to-HDL ratio improved significantly in the treatment group (P<0.001)
• IGF-1 levels increased by 81.0% (tesamorelin) vs. decreased by 5.0% (placebo) (P<0.001)
• No significant differences in glycemic measures were observed between groups

This study constitutes the primary evidence anchor for tesamorelin’s FDA-approval dossier and remains the most-cited tesamorelin publication in the peer-reviewed literature.

The 12-month randomized trial: Falutz et al. 2010 (JAIDS)

A 12-month study of 404 HIV-infected patients with excess abdominal fat examined both efficacy and durability of effect. Based on articles retrieved from PubMed, Falutz et al. in Journal of Acquired Immune Deficiency Syndromes (2010; PMID 20101189) reported:

• VAT decreased by -10.9% (-21 cm²) in the tesamorelin group versus -0.6% (-1 cm²) in placebo at 6 months (P<0.0001)
• Patients continuing tesamorelin through 12 months achieved approximately 18% total VAT reduction (P<0.001)
• Trunk fat, waist circumference, and waist-hip ratio all improved significantly with no change in limb or abdominal SC fat
• VAT reaccumulated rapidly in patients who switched from tesamorelin to placebo at month 6, indicating the effect is dependent on continued treatment
• No significant changes in glucose parameters; drug was well tolerated

The pooled phase-3 analysis: Falutz et al. 2010 (JCEM)

To provide greater statistical power, data from two multicenter phase-3 trials were pooled in an analysis of 806 ART-treated HIV patients randomized 2:1 to tesamorelin 2 mg/day or placebo. According to PubMed, Falutz et al. in The Journal of Clinical Endocrinology and Metabolism (2010; PMID 20554713) documented:

• At week 26: VAT decreased significantly in tesamorelin-treated patients (-24 ± 41 cm²) versus placebo (+2 ± 35 cm²) (P<0.001; treatment effect -15.4%)
• No significant change in abdominal subcutaneous adipose tissue (treatment effect -0.6%)
• Triglycerides: -37 ± 139 mg/dL (tesamorelin) versus +6 ± 112 mg/dL (placebo) (P<0.001)
• Cholesterol-to-HDL ratio treatment effect: -7.2% (P<0.001)
• At week 52 in the continuous-treatment group: VAT reduction maintained at -17.5% with preserved lipid improvements
• Significant improvements in patient- and physician-rated belly appearance scores (P<0.001 to 0.002)

Long-term safety extension: Falutz et al. 2008 (AIDS)

A 26-week safety extension phase evaluated tolerability and durability of effect through 52 total weeks. Based on articles retrieved from PubMed, Falutz et al. in AIDS (2008; PMID 18690162) confirmed that VAT reduction was sustained at approximately -18% at 52 weeks in those who continued tesamorelin treatment, while patients who discontinued experienced VAT reaccumulation. Glucose parameters remained non-significantly changed through 52 weeks. Adverse event prevalence during the extension was comparable to the initial phase, supporting a consistent safety profile over one year of treatment.

Metabolic responder analysis: Stanley et al. 2012 (Clinical Infectious Diseases)

A per-protocol analysis of 402 subjects from the phase-3 program stratified patients as tesamorelin “responders” (≥8% VAT reduction) or “non-responders” to assess whether VAT reduction itself drove metabolic improvement. According to PubMed, Stanley, Falutz et al. in Clinical Infectious Diseases (2012; PMID 22495074) found that responders experienced significantly greater triglyceride reduction, better preservation of glucose homeostasis (attenuated fasting glucose and HbA1c rise), and improved adiponectin levels compared to non-responders, suggesting the metabolic benefits are mechanistically linked to the degree of VAT reduction, not merely to tesamorelin exposure per se.

Summary of Tesamorelin’s Evidence Profile

How Does Tesamorelin Compare to Other GHRH Analogs?

Tesamorelin shares its fundamental mechanism, GHRH receptor agonism driving pulsatile pituitary GH secretion, with sermorelin (GHRH[1-29]) and CJC-1295 (a DAC-modified GHRH analog), both of which are studied as research compounds. The critical distinction is regulatory status:

• Tesamorelin (Egrifta): FDA-approved prescription drug; one specific indication; extensive phase-3 RCT evidence base; requires physician prescription
• Sermorelin: Research compound; no current FDA-approved indication; studied in preclinical and limited clinical contexts
• CJC-1295: Research compound; no FDA-approved indication; studied in early-phase clinical and preclinical contexts

Structurally, tesamorelin’s trans-3-hexenoic acid modification (yielding TH9507) extends plasma half-life by protecting the N-terminal Tyr-Ala bond from DPP-4 cleavage, a common degradation mechanism for native GHRH. This stabilization strategy is distinct from the drug-affinity complex (DAC) technology used in CJC-1295.

What Is Tesamorelin’s Prescription and Regulatory Status?

FDA (United States)

Tesamorelin received FDA approval in November 2010 as a prescription-only medication under the brand name Egrifta (Theratechnologies Inc.). An updated formulation, Egrifta SV (2 mg/mL concentrated solution), was subsequently approved. The approved indication is specifically: “reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.” Tesamorelin is regulated as a new molecular entity under 21 CFR. It is not available over the counter and is not a dietary supplement ingredient. All prescribing, dispensing, and use must occur within the bounds of FDA-approved labeling and applicable state pharmacy law.

International and Other Regulatory Contexts

Tesamorelin’s regulatory status outside the United States varies by jurisdiction. Researchers and clinicians in other countries should consult relevant national regulatory agencies for current approval status. The compound has been reviewed by Health Canada and other bodies in the context of HIV-associated lipodystrophy.

Frequently Asked Questions About Tesamorelin

Is tesamorelin FDA approved?

Yes, tesamorelin (brand name Egrifta) is FDA approved as a prescription medication for a specific indication: reduction of excess visceral abdominal fat in HIV-infected adults with HIV-associated lipodystrophy. This approval does not extend to other uses. It is a prescription drug requiring physician authorization; it cannot be legally obtained or used for other purposes under FDA-approved labeling.

How does tesamorelin work?

Tesamorelin is a stabilized synthetic GHRH analog that binds and activates GHRH receptors on anterior pituitary somatotrophs, stimulating pulsatile growth hormone secretion. The resulting GH elevation drives IGF-1 production and promotes preferential lipolysis in visceral adipose tissue, the mechanism underlying its clinically documented VAT reduction in HIV-associated lipodystrophy.

What did the tesamorelin phase-3 clinical trials show?

Two multicenter, double-blind, placebo-controlled phase-3 trials (pooled n=806), primarily led by Falutz et al. and published in the NEJM and JCEM, demonstrated approximately 15–18% visceral adipose tissue reduction at 26 weeks with daily subcutaneous tesamorelin 2 mg versus placebo (P<0.001). The effect was maintained at 52 weeks with continued treatment and reversed upon discontinuation. Triglycerides and cholesterol-to-HDL ratio also improved significantly, with no clinically meaningful changes in glucose parameters.

What is the difference between tesamorelin and sermorelin or CJC-1295?

All three are GHRH analogs activating pituitary GH secretion. Tesamorelin is the only one among them that is FDA approved as a prescription drug, for HIV-associated lipodystrophy only. Sermorelin and CJC-1295 are research compounds with no FDA-approved therapeutic indication. Tesamorelin’s TH9507 modification confers DPP-4 resistance and extended activity compared to native GHRH(1-44), which is distinct from the DAC technology used in CJC-1295.

Prescription medicine, research reference only. Tesamorelin (Egrifta) is an FDA-approved prescription medication for HIV-associated lipodystrophy; it is not available without a physician’s prescription. This article is for educational and research reference purposes only and does not constitute medical advice, does not describe off-label uses or dosing, and does not recommend human use of any compound outside its FDA-approved indication. Nothing here is intended to diagnose, treat, cure, or prevent any disease. All clinical findings referenced are sourced from published peer-reviewed literature and FDA labeling, read primary sources in full. According to PubMed, the primary citations are: Falutz et al., NEJM 2007 (DOI); Falutz et al., AIDS 2008 (DOI); Falutz et al., JAIDS 2010 (DOI); Falutz et al., JCEM 2010 (DOI); Stanley & Falutz et al., Clin Infect Dis 2012 (DOI). Consult a licensed physician for any personal health decisions. Must be 21+.

TL;DR: TB-500 is a synthetic peptide commercially marketed as a fragment of Thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein with documented roles in G-actin sequestration, cell migration, angiogenesis, and tissue repair. The published research base is predominantly preclinical, rodent and in vitro models, centered on the parent Tβ4 protein rather than the specific TB-500 fragment itself. No large human RCTs for any tissue-repair indication have been published as of 2026. TB-500 is not FDA approved and is explicitly prohibited by WADA under Section S2.

Research-Use Disclaimer: This article is for educational and research reference purposes only. TB-500 is a research peptide, not approved by the FDA for human use. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published preclinical research on Thymosin beta-4 and related peptides. For adults 21+ with a research interest only.

What Is TB-500? Definition, Origins, and the Tβ4 Relationship

TB-500 is the commercial name for a synthetic peptide fragment that corresponds to amino acids 17–23 of Thymosin beta-4 (Tβ4), a ubiquitous, naturally occurring 43-amino-acid protein found in virtually all mammalian nucleated cells. The sequence most commonly associated with the TB-500 commercial product is Ac-LKKTETQ (or variants thereof), selected on the basis that this region of the Tβ4 molecule is associated with actin-binding activity and cell migration in published research.

The scientific literature on this area is built almost entirely around full-length Thymosin beta-4, not the TB-500 fragment specifically. Researchers evaluating claims associated with TB-500 should be aware of this distinction: the mechanistic studies cited in this article document Tβ4 biology, and extrapolation to the truncated commercial fragment, while a reasonable scientific hypothesis, has not been independently validated with the same depth of evidence.

What Is the Core Mechanism? How Thymosin Beta-4 Interacts with Actin

The foundational mechanism of Thymosin beta-4, and the basis for all downstream tissue-repair hypotheses, is its role as a G-actin sequestering protein. Understanding this mechanism is essential context for interpreting the broader research literature.

What Does “G-Actin Sequestration” Mean in Research?

Actin exists in two forms in cells: G-actin (globular, monomeric, unpolymerized) and F-actin (filamentous, polymerized). Rapid transitions between these forms drive cell movement, migration, and shape changes. Thymosin beta-4 binds G-actin with micromolar affinity, holding actin monomers in a readily available but unpolymerized pool. When cells receive signals to migrate, during wound healing, immune activation, or angiogenesis, this sequestered pool releases and polymerizes rapidly, enabling fast cytoskeletal reorganization.

According to PubMed, a landmark 1992 study by Cassimeris et al. published in The Journal of Cell Biology demonstrated that Thymosin beta-4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes, and that chemoattractant stimulation reduces the G-actin/Tβ4 complex as polymerization proceeds, consistent with a dynamic regulatory role in cell motility (PMID: 1447300).

A 2007 review by Hannappel published in Annals of the New York Academy of Sciences traces the history of this discovery, noting that in 1990 Safer and colleagues first recognized that thymosin beta-4 sequesters G-actin with a dissociation constant in the micromolar range that allows fast binding and release, establishing beta-thymosins as the main intracellular G-actin-sequestering peptides in most vertebrate cells (PMID: 17468232).

What Research Contexts Has Thymosin Beta-4 Been Studied In?

Based on articles retrieved from PubMed, the Thymosin beta-4 literature spans several distinct preclinical research contexts. The following summarizes each major area with primary source citations.

1. Wound Healing and Skin Repair Models

A 2012 review by Goldstein, Hannappel, Sosne, and Kleinman published in Expert Opinion on Biological Therapy, among the most comprehensive summaries of Tβ4 biology, documents that after injury, Tβ4 is released by platelets, macrophages, and other cell types to protect cells and tissues from further damage, reduce apoptosis and inflammation, bind to actin, and promote cell migration including the mobilization, migration, and differentiation of stem/progenitor cells which form new blood vessels and regenerate tissue. The review also notes Tβ4 decreases myofibroblast numbers in wounds, resulting in reduced scar formation (PMID: 22074294).

A 2010 review by Philp and Kleinman (NIH/NIDCR) published in Annals of the New York Academy of Sciences specifically reviewed animal model evidence across dermal, corneal, and cardiac wound repair, concluding that Tβ4 studies in various animal models of disease and repair have provided the scientific foundation for ongoing clinical trials in dermal, corneal, and cardiac wound repair, indicating that the preclinical evidence was considered sufficient to advance to human trials in those specific contexts (PMID: 20536453).

2. Corneal and Ocular Repair Models

Corneal wound healing is one of the most extensively studied Tβ4 research contexts and the furthest advanced toward clinical translation. A 2002 study by Sosne, Szliter, Kleinman, and colleagues published in Experimental Eye Research demonstrated that topical Tβ4 treatment in a mouse alkali corneal injury model produced accelerated re-epithelialization at all time points and decreased PMN infiltration at 7 days post-injury compared to controls, with decreased mRNA levels for pro-inflammatory cytokines including IL-1β, MIP-1α, and MCP-1 (PMID: 11950239).

A 2018 review by Sosne published in Expert Opinion on Biological Therapy narrates the translational arc from bench to bedside, noting that Tβ4 has entered Phase 3 human clinical trials for dry eye disease and neurotrophic keratopathy, representing the most advanced clinical development of any Tβ4-related compound and one of the few contexts where human trial data exists (PMID: 30063853).

A 2023 review by Sosne and Berger published in International Immunopharmacology further describes Tβ4 as currently in Phase 3 human clinical trials for dry eye disease, with prior work demonstrating that topical Tβ4 as an adjunct reduces inflammatory mediators and PMN infiltrates while enhancing bacterial killing and wound healing pathway activation in P. aeruginosa keratitis models (PMID: 37018981).

3. Cardiac Research Models

A 2018 review by Hinkel, Klett, Bähr, and Kupatt published in Expert Opinion on Biological Therapy characterizes Tβ4’s documented role in cardiac preclinical research, noting that during cardiac development Tβ4 appears essential for vascularization of the myocardium, and in adult organisms Tβ4 has anti-inflammatory properties, increases myocyte and endothelial cell survival accompanied by differentiation of epicardial progenitor cells, with overexpression enhancing micro- and macrovasculature in ischemic myocardium and improving cardiac function in diabetic and dyslipidemic pig ischemic heart models (PMID: 30063857).

A 2015 review by Goldstein and Kleinman published in Expert Opinion on Biological Therapy synthesizes the broader preclinical-to-clinical translation picture, summarizing that Tβ4 has been used successfully in several clinical trials involving tissue repair and regeneration, with significant advances in understanding its direction of stem cell maturation and regeneration following injury, providing the scientific foundation for ongoing and projected trials in eye injuries, dermal wounds, cardiac repair following myocardial infarction, and brain healing following stroke (PMID: 26096726).

4. Neurological and Cell Migration Models

A 1993 study by Border and colleagues published in Journal of Neurochemistry investigated beta-thymosin expression in developing rat cerebellum, finding that Tβ4 expression in premigratory granule cells and in growing neuronal processes is consistent with the possibility that beta-thymosins are involved in the dynamics of actin polymerization during migration and process extension of neurons, establishing early evidence for Tβ4’s role in cell migration contexts beyond peripheral tissue (PMID: 8245965).

5. Actin-Sequestration, Nitric Oxide, and HIF-1α

A 2014 study by Ryu, Kang, and Moon published in PLoS ONE investigated interactions between Tβ4, nitric oxide, and hypoxia-inducible signaling in cell culture models, finding that the actin-sequestering protein Tβ4 is a novel target of hypoxia-inducible nitric oxide and HIF-1α regulation, with NO production and Tβ4 expression both increased under hypoxic conditions, and SNAP-1-induced cell migration decreased when Tβ4 was inhibited via siRNA, suggesting a mechanistic link between hypoxic signaling pathways and Tβ4-mediated cell motility (PMID: 25271630).

What Is the Honest Evidence Tier for TB-500?

Representing the evidence tier accurately requires distinguishing between two distinct bodies of work: the extensive preclinical literature on full-length Thymosin beta-4, and the very limited research on the specific TB-500 commercial fragment. The following table summarizes the landscape as documented in published literature:

The critical limitation to state plainly: The scientific rationale for TB-500 rests on extrapolating from Tβ4 biology to a truncated fragment. This is a coherent mechanistic hypothesis, the actin-binding region of Tβ4 does correspond to the fragment used, but it is not the same as having independent, peer-reviewed evidence for the specific commercial peptide. The absence of human RCTs for any tissue-repair indication, and the absence of independent peer review for the TB-500 fragment itself, places this compound firmly in the preclinical-only evidence tier.

What Is TB-500’s Regulatory and Anti-Doping Status?

FDA Status (United States)

TB-500, as a synthetic research peptide, is not approved by the U.S. Food and Drug Administration as a drug, biologic, or dietary supplement ingredient. The FDA has not authorized any therapeutic indication for TB-500 or for Thymosin beta-4 outside of the specific clinical trial contexts in which Tβ4 is currently being studied (corneal indications). Researchers should consult current FDA guidance directly for the most up-to-date classification status.

WADA Status (World Anti-Doping Agency)

TB-500 and Thymosin beta-4 are explicitly prohibited by the World Anti-Doping Agency under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics of the WADA Prohibited List. This is distinct from the S0 classification applied to some other research compounds; S2 specifically targets peptide growth factors and related substances due to their potential for performance-enhancing effects. The S2 prohibition applies both in-competition and out-of-competition for all athletes subject to WADA rules, and encompasses both the full-length Tβ4 protein and synthetic fragments or mimetics associated with it. Athletes in sanctioned sports should be aware that TB-500 is a prohibited substance under anti-doping regulations.

Frequently Asked Questions About TB-500

Is TB-500 FDA approved?

No. TB-500 is not approved by the FDA for any therapeutic use in humans. It is classified as a research peptide with no approved indication, no authorized human dosing protocol, and no legal status as a drug or dietary supplement in the United States. The related full-length protein Thymosin beta-4 has entered Phase 3 clinical trials for specific corneal indications, but this does not confer any approval to the TB-500 commercial fragment.

What does the TB-500 and Thymosin beta-4 research actually show?

Based on articles retrieved from PubMed, the peer-reviewed literature on Thymosin beta-4 documents consistent preclinical findings across G-actin sequestration, cell migration promotion, angiogenesis in injury contexts, anti-inflammatory activity, and tissue-repair effects in rodent models spanning wound healing, corneal injury, cardiac ischemia, and musculoskeletal contexts. The specific TB-500 commercial fragment has minimal independent published research. Human clinical data for tissue repair is absent; the most advanced human clinical work on Tβ4 relates to dry eye disease and corneal wound repair.

What is TB-500’s evidence tier?

TB-500 is a Tier 2 compound in the Legendary Labz framework, the parent protein Thymosin beta-4 has multiple peer-reviewed animal model studies with consistent mechanistic findings, but lacks the human RCT evidence required for Tier 1 classification, and the specific fragment has even less independent research than the full protein. Full evidence-tier methodology is documented in the guide.

Is TB-500 prohibited by WADA?

Yes. Thymosin beta-4 and related peptide fragments including TB-500 are prohibited by the World Anti-Doping Agency under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. This prohibition applies in-competition and out-of-competition and covers all athletes subject to WADA-compliant anti-doping programs. Note that TB-500 falls under S2 (not S0), reflecting its classification as a peptide growth factor-related substance rather than simply a non-approved substance.

Research use only. Not intended for human use. Not FDA approved. This article documents published scientific literature for educational and reference purposes and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. All citations link to primary sources, read them in full. TB-500 / Thymosin beta-4 is prohibited by WADA under Section S2. Must be 21+.

TL;DR: Sermorelin is a synthetic 29-amino acid analog of growth hormone-releasing hormone (GHRH), specifically the biologically active N-terminal fragment designated GHRH(1-29)-NH₂. It acts as a full agonist at the pituitary GHRH receptor, stimulating endogenous growth hormone secretion via a cAMP-mediated pathway. Sermorelin was formerly FDA-approved (as Geref) for GH-deficiency diagnostic testing and as a pediatric therapeutic, but the branded product was voluntarily withdrawn from the U.S. market and is no longer an approved drug. It is now most commonly encountered as a compounded preparation. Educational and research reference only, not a protocol guide or medical advice.

Research-Use Disclaimer: This article is for educational and research reference purposes only. Sermorelin is not currently approved by the FDA for human use as a marketed drug. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings referenced below are from published scientific literature. For adults 21+ with a research interest only.

What Is Sermorelin? Definition and Structure

Sermorelin, also written as sermorelin acetate or GHRH(1-29)-NH₂, is a synthetic peptide analog comprising the first 29 amino acids of endogenous human growth hormone-releasing hormone (GHRH), the 44-residue hypothalamic signaling peptide that governs pulsatile GH secretion from the anterior pituitary. The GHRH(1-29) fragment retains full biological activity at the GHRH receptor; the remaining C-terminal residues (30–44) of native GHRH contribute structural stability but are not required for receptor binding or activation.

Its amino acid sequence is: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂. The C-terminal amide group (-NH₂) is a synthetic modification that enhances metabolic stability relative to unmodified peptide chains.

How Does Sermorelin Work? The GHRH Receptor Mechanism

Sermorelin’s mechanism of action is well-characterized in the published pharmacology literature. Unlike synthetic GH secretagogues (such as ipamorelin or GHRP-6) which act at the ghrelin/GHS receptor, sermorelin acts exclusively through the pituitary-type GHRH receptor (pGHRH-R), a G protein-coupled receptor (GPCR) expressed on somatotroph cells in the anterior pituitary gland.

How does sermorelin stimulate GH secretion at the cellular level?

Sermorelin binds the GHRH receptor on pituitary somatotrophs, activating adenylyl cyclase and elevating intracellular cyclic adenosine monophosphate (cAMP) concentrations. The resulting cAMP surge activates protein kinase A (PKA), which in turn promotes calcium influx and triggers the exocytotic release of stored GH granules. This is the same molecular cascade used by endogenous GHRH, sermorelin is a full agonist, not a partial agonist or modulator.

Based on articles retrieved from PubMed, a 1989 study by Cheng et al., published in Endocrinology, investigated GHRH(1-29) ([N-Ac-Tyr¹, D-Arg²]GRF-1-29 used as antagonist reference) in rat primary pituitary cell culture, demonstrating that GRF (GHRH) increased intracellular cAMP by approximately 3-fold and that GH release was dose-dependent and time-dependent. A 1996 study by Wu et al., published in the Journal of Endocrinology, further characterized the cAMP pathway, showing that pharmacological blockade of adenylyl cyclase (with MDL 12, 330A) prevented both cAMP accumulation and GH release in response to GHRH, while cAMP antagonists (Rp-cAMP) also blocked GH secretion, confirming that the cAMP pathway is obligate for GHRH receptor-mediated GH release, not merely modulatory.

What distinguishes the GHRH receptor pathway from other GH secretagogue mechanisms?

The distinction matters for understanding sermorelin’s mechanism precisely. The GHRH receptor pathway (sermorelin’s target) primarily operates through cAMP elevation and is somatostatin-sensitive, meaning somatostatin, the hypothalamic GH-inhibiting hormone, can suppress the GHRH-stimulated GH pulse at the pituitary level. This is in contrast to ghrelin-type secretagogues (GHRP-6, ipamorelin), which operate through a distinct receptor (GHS-R) and a largely cAMP-independent calcium-mobilization pathway. The two pathways are synergistic when combined, a pharmacological property exploited in research on combined secretagogue protocols.

Sermorelin’s History: From Hypothalamic Science to FDA Approval and Discontinuation

What is the origin of GHRH science and how did sermorelin emerge from it?

The discovery of endogenous GHRH was a landmark in neuroendocrinology. As documented in a comprehensive 1986 review by Grossman, Savage, and Besser in Clinics in Endocrinology and Metabolism, human GHRH was originally extracted from pancreatic tumors in two patients with acromegaly and was found to consist of a 44-residue amidated peptide along with C-terminally shortened derivatives, the latter establishing that the N-terminal fragment retained full activity. The 1986 review noted that “analogues of GHRH are useful in the investigation of the hypothalamopituitary axis, and may be important in the therapy of short stature.” Sermorelin, the GHRH(1-29) fragment, emerged from this early characterization as the shortest fully active sequence, and became the primary research tool and eventual clinical formulation.

What did early clinical research on GHRH(1-29) in GH-deficient children show?

Based on articles retrieved from PubMed, the clinical evidence for GHRH(1-29) in pediatric GH deficiency was established across several trials in the 1980s and early 1990s. A pivotal 1987 study by Ross et al. in The Lancet treated 18 prepubertal GH-deficient children with twice-daily subcutaneous injections of GHRH(1-29)-NH₂, finding that 8 of the 18 children showed a worthwhile response defined as an increase in height velocity of greater than 2 cm/yr, with a range of 2.7–11.2 cm/yr among responders, and that this increase was maintained over 6–18 months of treatment. The study also noted that a pretreatment peak serum GH response above 30 mU/l during an intravenous GHRH test was predictive of a good growth response.

A 1993 randomized controlled trial by Chen et al., published in Acta Paediatrica Supplement, compared two doses of GHRH(1-29)-NH₂ to GH therapy in 60 children with hypothalamic-origin GH deficiency. Mean height velocities at 6 months were 9.2 and 9.3 cm/year for the two GHRH dose groups versus 14.6 cm/year for the GH group, demonstrating that while GHRH(1-29) produced meaningful growth acceleration, standard GH therapy was statistically superior. The authors concluded that continuous-infusion GHRH(1-29) was unlikely to be as effective as GH for promoting growth in GH-deficient children.

A 1997 multicenter study by Ogilvy-Stuart et al. in Clinical Endocrinology extended this to children with radiation-induced GH deficiency, reporting a significant increase in height velocity from 3.3 cm/year before treatment to 6.0 cm/year after one year of GHRH(1-29)-NH₂ (P = 0.004), with no adverse changes in biochemical or hormonal analyses. Following the study year, GH therapy produced 7.5 cm/year, again higher, though not directly comparable given different populations.

What Was Sermorelin’s FDA-Approved Status (Geref) and Why Was It Discontinued?

Sermorelin was FDA-approved in the United States under the brand name Geref (manufactured by Serono Laboratories). The approved indications included:

• Diagnostic use: evaluation of the ability of the somatotrophs of the anterior pituitary gland to release GH (the “sermorelin stimulation test”), used to evaluate children with suspected GH deficiency
• Therapeutic use: treatment of idiopathic GH deficiency in children with growth failure

Geref was voluntarily withdrawn from the U.S. market by the manufacturer, not removed for safety or efficacy reasons. The withdrawal was a business decision by Serono; this distinction is important because voluntary withdrawal does not carry the same meaning as FDA-initiated market removal. As a consequence, sermorelin no longer has an active, FDA-approved New Drug Application (NDA) in the United States and is not currently a legally marketed pharmaceutical drug.

Following the withdrawal of Geref, sermorelin has been most commonly encountered as a compounded preparation prepared by 503A/503B compounding pharmacies. The regulatory landscape for compounded peptides, including sermorelin, has been subject to ongoing FDA guidance changes, particularly following the Compounding Quality Act and subsequent FDA communications on bulk drug substances. Researchers and clinicians should consult current FDA guidance on compounded peptide status directly, as this area of regulation has continued to evolve through 2025 and beyond.

What Is Sermorelin’s Evidence Tier? An Honest Assessment

Because sermorelin was a formerly approved therapeutic compound, its evidence profile differs meaningfully from most research peptides that have only preclinical data. The table below summarizes the evidence landscape:

The critical context: Sermorelin’s former approval status means it has a richer human evidence base than many research peptides. However, that history applies specifically to pediatric GH-deficiency indications under an approved protocol, it does not generalize to all proposed uses. The evidence should be read in the context for which it was generated: primarily pediatric growth hormone axis evaluation and GH-deficiency therapy in children with documented hypothalamic-origin deficiency.

How Does Sermorelin Compare to Other GHRH-Family Analogs?

Understanding sermorelin’s place in the GHRH analog landscape requires distinguishing it from structurally related compounds:

• CJC-1295: A modified GHRH(1-29) analog with a Drug Affinity Complex (DAC) modification that extends its half-life by binding endogenous albumin. CJC-1295 was studied for its prolonged GH-releasing profile; sermorelin has a much shorter active half-life.
• Tesamorelin: A GHRH analog (trans-3-hexenoic acid modification to native GHRH) that received FDA approval (as Egrifta) for HIV-associated lipodystrophy, the only GHRH analog currently holding an active FDA approval in the United States as of 2026.
• Native GHRH (1-44): The full-length endogenous form; sermorelin retains the biologically active N-terminal 29 residues with equivalent receptor activity but shorter metabolic half-life than the full sequence.

Based on research retrieved from PubMed, Schally et al. published work in 2018 in Proceedings of the National Academy of Sciences characterizing GHRH agonist activity, demonstrating that GHRH agonists act on pituitary GHRH receptor splice variants (pGHRH-R and SV1) and that receptor down-regulation is a documented response to sustained agonist exposure, a pharmacological consideration relevant to any discussion of the GHRH agonist class.

Frequently Asked Questions About Sermorelin

What is sermorelin and how does it differ from GHRH?

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) comprising the biologically active N-terminal 29 amino acids of the native 44-residue hypothalamic peptide, hence the designation GHRH(1-29)-NH₂. It binds the pituitary GHRH receptor and stimulates endogenous growth hormone secretion through the same cAMP-mediated pathway as full-length GHRH, but with a shorter sequence that retains full agonist activity. The C-terminal amide group improves metabolic stability compared to unmodified fragments.

Was sermorelin ever FDA approved?

Yes, with important regulatory nuance. Sermorelin was previously FDA-approved under the brand name Geref (Serono) for diagnostic evaluation of pituitary GH-secretory capacity and for treatment of idiopathic GH deficiency in children. The branded product was voluntarily withdrawn from the U.S. market by the manufacturer, not removed for safety or efficacy violations. Sermorelin is therefore not currently an FDA-approved drug, and is most often encountered today as a compounded preparation under evolving regulatory frameworks.

What does the research show about sermorelin stimulating GH release?

Based on articles retrieved from PubMed, sermorelin (GHRH 1-29) stimulates GH release from pituitary somatotrophs by binding the GHRH receptor and elevating intracellular cAMP in a dose-dependent manner. Clinical studies in GH-deficient children published in The Lancet (Ross et al., 1987) documented meaningful increases in height velocity, 8 of 18 treated children increased height velocity by more than 2 cm/year. A 1993 randomized trial (Chen et al.) showed GHRH(1-29) produced height velocity of approximately 9 cm/year versus 14.6 cm/year for GH therapy, indicating efficacy but inferiority to direct GH replacement in that population.

What is sermorelin’s current regulatory and compounding status in the United States?

Sermorelin does not hold an active FDA NDA; the branded Geref was voluntarily discontinued. Compounding pharmacies have prepared sermorelin under Section 503A/503B of federal law, but the regulatory landscape governing compounded peptides has shifted significantly since 2020, with the FDA issuing updated guidance on bulk drug substances. Researchers and clinicians should consult current FDA guidance on compounded peptide status directly; this area of regulation continues to evolve.

Research use only. Not intended for human use. Sermorelin is not currently an FDA-approved drug; the branded product Geref was voluntarily withdrawn from the U.S. market. This article documents published scientific literature and regulatory history for educational and reference purposes and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. All citations link to primary sources, read them in full. Must be 21+.

TL;DR: Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of the ACTH(4-10) fragment of adrenocorticotropic hormone, developed in Russia and studied primarily in Russian preclinical and early clinical research. The peer-reviewed literature documents Semax’s association with BDNF and NGF upregulation, neuroprotective effects in rodent models of cerebral ischemia, and modulation of neurotrophin receptor signaling. Semax is approved for clinical use in Russia; it is not FDA approved and is classified as a research compound in the United States and European Union.

Research-Use Disclaimer: This article is for educational and research reference purposes only. Semax is not approved by the FDA for human use in the United States. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published preclinical and early-phase research, predominantly from Russian institutions. For adults 21+ with a research interest only.

What Is Semax? Definition and Origins

Semax is a synthetic heptapeptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is an analog of the N-terminal fragment spanning positions 4 through 10 of adrenocorticotropic hormone (ACTH), specifically ACTH(4-10), with a C-terminal Pro-Gly-Pro (PGP) tripeptide extension added to confer metabolic stability in biological fluids.

The compound was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, primarily by researcher Nikolay Myasoedov and colleagues, over several decades beginning in the 1980s. A key design goal was to retain the cognitive and neuroprotective activity attributed to the ACTH(4-10) fragment while removing its hormonal effects entirely. The result is a peptide that, per the published literature, is “completely devoid of any hormonal activity” while retaining CNS-relevant biological effects in rodent models.

What Is Semax’s Documented Mechanism? What the Research Shows

Semax does not operate through a single well-characterized receptor target in the manner of, for example, a receptor agonist or enzyme inhibitor. The peer-reviewed literature describes it as a pleiotropic neuropeptide whose documented effects span multiple neurobiological systems. The most consistently reported mechanistic findings are detailed below, each anchored to published research retrieved from PubMed.

Does Semax Upregulate BDNF? Evidence from Rodent Studies

The most replicated finding in the Semax literature is its association with upregulated brain-derived neurotrophic factor (BDNF) expression in the rat brain following intranasal administration.

A 2006 study by Dolotov et al., published in Brain Research, examined the effect of a single intranasal Semax application (50 µg/kg body weight) in male Wistar rats. The study documented a maximal 1.4-fold increase in BDNF protein levels, a 1.6-fold increase in trkB tyrosine phosphorylation, and a 3-fold increase in exon III BDNF mRNA levels in the rat hippocampus. Semax-treated animals also showed an increased number of conditioned avoidance reactions. The authors concluded that Semax affects cognitive brain functions by modulating expression and activation of the hippocampal BDNF/trkB system (PMID 16996037).

A companion 2006 study by the same group, published in the Journal of Neurochemistry, investigated Semax binding and BDNF protein changes in rat basal forebrain. Specific, reversible Semax binding sites were identified on cell membranes isolated from the basal forebrain (dissociation constant KD 2.4 ± 1.0 nM), and intranasal application at 50 and 250 µg/kg produced rapid increases in BDNF protein levels in the basal forebrain at 3 hours post-application, without significant effects in the cerebellum, suggesting region-specific activity (PMID 16635254).

An earlier 2003 publication by Dolotov et al. in Doklady Biological Sciences also documented BDNF stimulation across multiple rat brain areas in vivo, providing the initial in vivo confirmation that preceded the more detailed mechanistic studies (PMID 14556513).

How Does Semax Affect NGF and Neurotrophin Gene Expression?

Beyond BDNF, the literature documents Semax’s effects on nerve growth factor (NGF) and the broader neurotrophin signaling network, with effects that are region-specific and time-dependent.

A 2007 study by Agapova et al., published in Neuroscience Letters, examined rapid neurotrophin gene expression changes in rat brain one hour after intranasal Semax administration (50 µg/kg, single application). Real-time PCR analysis found that Semax increased NGF and BDNF gene expression in rat hippocampus, with BDNF also upregulated in the brainstem and cerebellum, while NGF expression decreased in the frontal cortex, a pattern the authors characterized as rapid, gene-specific, and brain-region-specific (PMID 17353092).

A subsequent 2009 study by Shadrina et al., published in the Journal of Molecular Neuroscience, extended this investigation across six time points (20 min to 24 h) and three brain regions. The study documented multidirectional, time-dependent changes in both NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina following Semax administration, with BDNF levels significantly increased in the retina 90 minutes after administration (PMID 19662538).

What Does the Cerebral Ischemia Research Show?

A central strand of the Semax research program concerns its behavior in rodent models of cerebral ischemia, a context in which Semax has also been studied clinically in Russia for stroke rehabilitation.

A 2009 study by Dmitrieva et al., published in Cellular and Molecular Neurobiology, examined neurotrophin and receptor gene expression following permanent middle cerebral artery occlusion (pMCAO) in rats treated with either Semax or its C-terminal PGP tripeptide. The study documented that Semax selectively activated transcription of BDNF, NT-3, and NGF, as well as their Trk receptors, in the ischemic rat cortex at 3, 24, and 72 hours after occlusion, a profile distinct from the non-selective effects of PGP alone (PMID 19633950).

A 2011 Russian-language study by Stavichansky et al. (with English abstract), published in Molekuliarnaia Biologiia, examined bilateral common carotid artery occlusion in rats and reported that Semax and PGP affected neurotrophin and receptor mRNA expression predominantly in the frontal cortex and hippocampus of ischemic animals, with the maximal neuroprotective effect of both peptides observed in the hippocampus 12 hours after occlusion. Ischemia-induced decreases in neurotrophin gene expression were substantially reversed by Semax treatment (PMID 22295573).

An earlier 1998 study by Iasnetsov et al. in Aviakosmicheskaia i Ekologicheskaia Meditsina compared multiple nootropic agents including Semax in rat models of bilateral carotid occlusion and hypoxic amnesia, and reported that Semax significantly increased animal survivability following bilateral carotid occlusion and partially or completely prevented mnestic (memory) disorders in ischemic rats, one of the earlier preclinical accounts of its neuroprotective profile (PMID 9606516).

What Is the Proposed Role of Semax in Dopaminergic and BDNF-Related Pathways?

A 2006 hypothesis paper by Tsai, published in Medical Hypotheses, proposed a mechanistic framework connecting Semax’s documented effects to dopaminergic and BDNF-related neurodevelopmental pathways. The paper noted published evidence that Semax can augment the effects of psychostimulants on central dopamine release and stimulates central BDNF synthesis, and proposed that these combined properties warranted further investigation in animal models of neurodevelopmental conditions. The paper was explicit that this represented a hypothesis for further exploration in animal models, not established therapeutic evidence (PMID 16996699). It is cited here as an example of the mechanistic hypotheses in the literature, not as evidence of clinical efficacy for any condition.

What Does the Only Available Clinical Trial Data Show?

In 2018, Gusev et al. published a clinical study in Zhurnal Nevrologii i Psikhiatrii (Journal of Neurology and Psychiatry, Russian-language) examining Semax administration in 110 post-ischemic stroke patients across early and late rehabilitation groups. The study reported that Semax administration increased plasma BDNF levels and was associated with accelerated improvement in Barthel index scores and motor performance, regardless of rehabilitation timing (PMID 29798983). This is one of the few human-subject studies in the English-indexed PubMed literature. Its design, non-blinded, Russian clinical context, moderate sample size, means it does not constitute the large placebo-controlled RCT evidence required for Western regulatory approval or Tier 1 classification.

What Is Semax’s Evidence Tier? An Honest Assessment

The following table summarizes the evidence landscape for Semax as documented in published, peer-reviewed literature. This is not a clinical assessment and does not represent medical guidance.

The critical limitation to state plainly: The Semax research base is substantially narrower in geographic diversity than that of many other research peptides. The majority of published studies originate from a relatively small number of Russian institutions, and independent replication in Western peer-reviewed literature is limited. Animal model findings, even well-replicated ones, do not establish human efficacy or safety. The BDNF/NGF upregulation observed in rodent models is a mechanistic finding; it does not constitute evidence that Semax produces equivalent neurotrophic effects in humans, or that such effects would translate to clinical benefit for any condition.

What Is Semax’s Regulatory Status?

FDA (United States)

Semax is not approved by the U.S. Food and Drug Administration as a drug, biologic, or dietary supplement ingredient. It has no approved human indication, no authorized dosing protocol, and is not legally available as a pharmaceutical in the United States. Researchers should consult current FDA guidance directly for its status under import and compounding regulations.

Russia

Semax is registered and approved for clinical use in Russia, where it has been used as an intranasal pharmaceutical for neurological indications including stroke rehabilitation. This approval reflects the regulatory standards and clinical trial requirements of the Russian Ministry of Health, which differ from FDA or EMA approval processes.

EU and Other Western Jurisdictions

Semax holds no EMA (European Medicines Agency) approval and is not registered as a medicinal product in the European Union. Regulatory status in individual member states may vary; researchers should consult the relevant national authority.

Frequently Asked Questions About Semax

What is Semax?

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of the ACTH(4-10) fragment of adrenocorticotropic hormone, developed in Russia and studied in peer-reviewed research for neurotrophic and neuroprotective properties in rodent models. It has no hormonal activity. It is approved for clinical use in Russia and classified as a research compound in the United States.

How does Semax affect BDNF and NGF?

In rodent studies, intranasal Semax administration has been documented to increase BDNF protein levels in the hippocampus and basal forebrain, upregulate BDNF and NGF mRNA expression in a region-specific and time-dependent manner, and activate transcription of neurotrophin receptors (trkA, trkB, trkC) in models of cerebral ischemia. These are preclinical findings; human neurotrophin responses have not been characterized in large controlled trials.

Is Semax FDA approved?

No. Semax is not approved by the FDA for any therapeutic use in the United States. It is registered for clinical use in Russia under different regulatory standards. It has no FDA-approved indication, no authorized human dosing guidance, and is not legally available as a drug or supplement in the United States.

What is Semax’s evidence tier?

Semax is a Tier 2 compound in the Legendary Labz framework: a meaningful body of peer-reviewed preclinical animal data with consistent neurotrophin and neuroprotection findings, supplemented by limited early-phase human trial data, but lacking the large placebo-controlled RCTs required for Tier 1 classification. The research base is geographically concentrated in Russian institutions with limited independent Western replication. Full evidence-tier methodology is documented in the guide.

Research use only. Not intended for human use. Not FDA approved. Semax is approved for clinical use in Russia; it is not approved by the U.S. Food and Drug Administration or the European Medicines Agency for any indication. This article documents published scientific literature for educational and reference purposes and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. All citations link to primary sources, read them in full. Must be 21+.

TL;DR: Selank (TP-7) is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed in Russia as an analog of the immunomodulatory tetrapeptide tuftsin. Preclinical research, largely from Russian institutions, has documented effects on GABAergic signaling, BDNF expression, enkephalin-degrading enzyme activity, and cytokine modulation in rodent and in vitro models. Selank is not FDA approved. It has been registered and studied in Russia. The overall evidence base is limited, concentrated in early-phase and non-English literature, and does not establish clinical safety or efficacy in humans.

Research-Use Disclaimer: This article is for educational and research reference purposes only. Selank is a research compound, not approved by the FDA for human use in the United States. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published preclinical research. For adults 21+ with a research interest only.

What Is Selank? Definition, Structure, and Origins

Selank, also designated TP-7 in earlier literature, is a synthetic heptapeptide with the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structurally modified analog of tuftsin, an endogenous tetrapeptide (Thr-Lys-Pro-Arg) naturally cleaved from immunoglobulin G and known for its role in stimulating macrophage activity and immune function.

The design rationale documented in the research literature centers on a key limitation of native tuftsin: rapid enzymatic degradation. Researchers extended the tuftsin sequence with the tripeptide Pro-Gly-Pro, a fragment also found in collagen and studied for its own CNS-modulating properties, to yield a compound with greater metabolic stability and prolonged biological activity. The resulting heptapeptide was reported in early studies to retain tuftsin’s immunomodulatory properties while acquiring anxiolytic and nootropic-like effects in rodent behavioral models.

What Mechanisms Has Selank Research Documented?

Selank’s documented mechanistic profile spans several biological pathways, which is consistent with its structural derivation from tuftsin, a pleiotropic immunomodulatory peptide. The mechanisms described below are drawn from published preclinical research; they represent observed associations in experimental models, not established clinical mechanisms of action.

1. GABAergic Signaling: Positive Allosteric Modulation

One of the most directly studied molecular mechanisms of Selank involves its interaction with the GABA receptor system. A 2018 study by Vyunova et al. published in Protein and Peptide Letters used radioligand-receptor analysis to investigate Selank’s binding behavior at GABA receptors in rat brain membrane preparations. The study documented that Selank modulated [³H]GABA binding as a positive allosteric modulator in a subtype-selective, concentration-dependent manner, and further showed that the joint action of Selank with benzodiazepines (diazepam and olanzapine) was non-cumulative and distinct from either substance alone, suggesting partially overlapping but non-identical binding sites. The investigators proposed positive allosteric modulation of GABA-A receptors as one of Selank’s anti-anxiety molecular mechanisms.

Consistent with this GABAergic hypothesis, a 2017 study by Kasian et al. in Behavioural Neurology examined Selank and diazepam separately and in combination in Wistar rats under unpredictable chronic mild stress conditions using the elevated plus maze test. The study found that individual administration of Selank was most effective in reducing anxiety induced by chronic compound administration, while combined Selank-diazepam treatment was most effective in reducing anxiety under chronic stress conditions, a finding the authors interpreted as consistent with a shared but not fully overlapping mechanism with classical benzodiazepines.

2. BDNF Expression in the Hippocampus

Brain-derived neurotrophic factor (BDNF) is a neurotrophin with documented roles in synaptic plasticity, learning, and memory consolidation. Selank’s documented relationship with BDNF has been examined in both acute and chronic experimental contexts.

A 2008 study by Inozemtseva et al., published in Doklady Biological Sciences, administered Selank intranasally to male Wistar rats and used RT-PCR and immunoenzymatic assay to measure BDNF mRNA and protein levels in the hippocampus in vivo. The study documented that intranasal administration of Selank produced changes in hippocampal BDNF expression, providing an early in vivo evidence point for neurotrophin involvement in Selank’s observed effects.

This BDNF-modulating effect was extended in a 2019 study by Kolik et al. in the Bulletin of Experimental Biology and Medicine, which evaluated Selank in rats exposed to chronic ethanol (10% solution as the sole fluid source for 30 weeks). Selank (0.3 mg/kg/day, 7 days, intraperitoneally) prevented ethanol-induced increases in BDNF content in the hippocampus and frontal cortex, and produced a cognitive-stimulating effect on the object recognition test in animals not exposed to ethanol. The authors concluded that neurotrophin mechanisms related to BDNF production are involved in Selank’s observed cognitive effects in this rodent model.

3. Enkephalin-Degrading Enzyme Activity

Tuftsin and its analogs have been studied in relation to peptidase activity, particularly enkephalin-degrading enzymes. Enkephalins are endogenous opioid pentapeptides involved in pain modulation, stress responses, and mood regulation. Research into Selank’s structural fragments has documented interactions with peptidase systems that regulate enkephalin half-life, a mechanism that has been proposed as one route through which Selank may extend the functional duration of endogenous opioid signaling in preclinical models.

The importance of Selank’s metabolic stability relative to native tuftsin was highlighted in studies identifying the Pro-Gly-Pro extension as critical for prolonged in vivo activity, as the native tuftsin sequence is rapidly cleaved by serum enzymes. A 2010 study by Andreeva et al. in Doklady Biological Sciences examined the antiviral properties of Selank’s structural fragments, isolating Gly-Pro as a pharmacophoric fragment with documented biological activity, which is consistent with the broader understanding that Selank’s metabolic breakdown products themselves may retain bioactivity and interact with peptidase systems.

4. Immunomodulation: Cytokine and Chemokine Gene Expression

Reflecting its structural derivation from tuftsin, Selank has been studied for immunomodulatory effects distinct from its behavioral profile. A 2011 study by Kolomin et al. in the Russian-language journal Genetika administered Selank and its fragments to mice and measured mRNA levels of chemokines, cytokines, and their receptors in the spleen at 6 and 24 hours post-administration. The study documented significant changes in the expression of the genes under study following Selank and its minimum active fragment (Gly-Pro) administration, supporting an immunomodulatory mechanism consistent with the tuftsin pharmacological profile and distinct from the GABAergic anxiolytic mechanism.

5. Anxiolytic-Like and Cognitive Behavioral Effects in Rodent Models

The largest body of Selank preclinical research involves behavioral testing in rodent anxiety and cognitive models. A 2003 study by Kozlovskii and Danchev in Neuroscience and Behavioral Physiology evaluated Selank (300 µg/kg) versus piracetam (400 mg/kg) using a conditioned active avoidance reflex paradigm in Wistar rats stratified by initial learning ability. Selank significantly activated learning in rats with initially poor performance, with progressive improvement across repeated administration days; the authors compared its nootropic-like dynamic profile favorably to piracetam in this model.

A 2006 study by Czabak-Garbacz et al. in Pharmacological Reports examined long-term Selank (TP-7) administration in Wistar rats with high initial emotional reactivity using Rodina’s behavioral method. Selank significantly reduced anxiety-phobic-like behavior from the second day of administration, with effects persisting across four weeks of the experiment and without producing changes in body weight, which the authors noted as consistent with an anxioselective profile.

In addiction-model contexts, a 2022 study by Konstantinopolsky et al. in the Bulletin of Experimental Biology and Medicine evaluated Selank in a naloxone-precipitated morphine withdrawal model in rats. A single intraperitoneal injection of Selank (0.3 mg/kg) reduced the total withdrawal syndrome index by approximately 40%, attenuated convulsive reactions and posture disorders, and increased tactile sensitivity threshold in morphine-dependent rats, with effects described as slightly inferior to, but comparable in direction to, diazepam (2 mg/kg).

What Is Selank’s Evidence Tier? An Honest Assessment

The evidence base for Selank has notable structural limitations that should be stated plainly for any researcher reviewing this compound.

The critical limitation to state plainly: the concentration of Selank’s published research within a small set of Russian laboratories, primarily the V. V. Zakusov Research Institute of Pharmacology and the Institute of Molecular Genetics, Russian Academy of Sciences, limits what independent replication can be claimed. This is not evidence of fraud, but it is a significant epistemic limitation. Furthermore, rodent behavioral models of anxiety-like behavior do not reliably translate to human clinical outcomes. The research is scientifically interesting and mechanistically coherent, but the honest evidence tier is low by international standards.

What Is Selank’s Regulatory Status?

United States (FDA)

Selank is not approved by the U.S. Food and Drug Administration as a drug, biologic, or dietary supplement ingredient. It has no authorized human therapeutic indication, no approved dosing protocol, and is classified as a research compound in the United States. Researchers should consult current FDA guidance directly.

Russia

Selank has been registered in Russia as a pharmaceutical drug (nasal drops formulation) for use as an anxiolytic. This registration reflects the regulatory framework of the Russian Ministry of Health and does not confer approval status in the United States, European Union, or other Western regulatory jurisdictions. Russian registration studies exist but are not widely accessible in the English-language literature.

Frequently Asked Questions About Selank

What is Selank?

Selank (TP-7) is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed in Russia as an analog of the endogenous immunomodulatory tetrapeptide tuftsin. It was designed with an extended Pro-Gly-Pro tail to improve metabolic stability relative to native tuftsin. It has been studied in preclinical rodent models for anxiolytic-like activity, cognitive behavioral effects, BDNF modulation, and immunomodulatory properties.

Is Selank FDA approved?

No. Selank is not approved by the FDA for any therapeutic use in humans. It has been registered and studied in Russia, where a nasal formulation is approved as an anxiolytic drug. In the United States, it has no approved indication, no authorized human dosing protocol, and is not legally available as a drug or dietary supplement.

How does Selank work, according to research?

Based on preclinical studies, Selank has been documented to act as a positive allosteric modulator of GABA receptors in rat brain membrane preparations, to regulate BDNF expression in the rat hippocampus following intranasal administration, and to influence cytokine and chemokine gene expression in mouse models consistent with immunomodulatory activity inherited from its tuftsin parent structure. These are observed research associations, not established clinical mechanisms, and have not been confirmed in large-scale human trials.

What is Selank’s evidence tier?

Selank is a Tier 2–3 compound in the Legendary Labz framework: a meaningful body of preclinical rodent and in vitro research exists, and limited early-phase human-use data from Russia is referenced in the literature. However, large placebo-controlled international RCTs are absent, independent replication outside Russian institutions is limited, and much of the primary data is in Russian-language sources with restricted international accessibility. Full evidence-tier methodology is documented in the guide.

Research use only. Not intended for human use. Not FDA approved. Selank has been studied and registered in Russia; it is not approved for human therapeutic use in the United States. This article documents published scientific literature for educational and reference purposes and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. All citations link to primary sources, read them in full. Must be 21+.

TL;DR: A Certificate of Analysis (CoA) is the primary analytical document that characterizes a batch of synthetic research peptide. A complete CoA covers seven distinct fields: identity (mass spectrometry or MALDI-TOF), chromatographic purity (RP-HPLC), net peptide content (gravimetric), residual moisture, counter-ion identity and load, endotoxin level (LAL assay), and physical appearance. Each field is generated by a separate analytical method and answers a different research question. A CoA issued by an accredited independent laboratory carries substantially more evidentiary weight than an in-house vendor self-report. Understanding how to read every field is a prerequisite for rigorous research-grade quality control.

Research-Use Disclaimer: This article is for educational and research reference purposes only. It describes analytical chemistry methods and quality-control criteria as they apply to synthetic research peptides evaluated as laboratory compounds. Nothing in this article constitutes medical advice, dosing guidance, or instruction for human use of any compound. All content is drawn from published analytical chemistry literature and is intended for researchers and professionals working in laboratory settings. For adults 21+ with a research interest only.

What Is a Certificate of Analysis and Why Does It Matter for Peptide Research?

A Certificate of Analysis (CoA) is a formal analytical document that reports the measured properties of a specific manufacturing batch of a synthetic compound. For research peptides, it is the principal instrument by which the chemical identity, purity, and compositional characteristics of a vial’s contents can be evaluated against defined specifications. Without a CoA, a researcher cannot confirm that a compound is what the label states, what percentage of the vial weight is actual peptide, or whether batch-to-batch variation has introduced analytically significant differences between experiments.

Research peptides are synthesized primarily via solid-phase peptide synthesis (SPPS), a stepwise process in which amino acids are assembled on a resin support. Even well-optimized SPPS workflows generate a mixture of products: the target sequence alongside truncated sequences (synthesis stopped early), deletion peptides (one or more amino acids skipped), oxidation products, and residual protecting groups or reagent impurities. The CoA translates the output of analytical methods run on the final product into a document that researchers can evaluate without conducting the underlying assays themselves.

The analytical standards most commonly referenced in peptide CoA documentation include those published by the United States Pharmacopeia (USP), particularly USP general chapters on HPLC (<621>) and bacterial endotoxins (<85>), and practices consistent with ICH Q6A specifications for identity and purity of synthetic small molecules and peptides.

The Seven CoA Fields Explained

A complete research-grade peptide CoA contains seven analytically distinct fields. Each field is generated by a different instrument or method and answers a different question about the material. Researchers should verify that all seven are present; a CoA that omits any of them is incomplete for rigorous QC purposes.

Identity: Mass Spectrometry and MALDI-TOF

The identity field on a peptide CoA is generated by mass spectrometry, either electrospray ionization mass spectrometry (ESI-MS) or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF). Both techniques measure the molecular weight of the compound by detecting the mass-to-charge ratio (m/z) of ionized molecules. The measured molecular weight is compared to the theoretical molecular weight calculated from the target amino acid sequence.

An identity confirmation requires that the measured monoisotopic or average molecular weight falls within the instrument’s mass accuracy window, typically ±1 Da or better for most research-grade ESI-MS instruments. A correct mass confirms that the compound contains the expected number and type of atoms for the stated sequence. It does not confirm sequence order (isomers with the same composition have identical masses), which is why mass spec identity confirmation is a necessary but not fully sufficient characterization in isolation.

MALDI-TOF is particularly common in peptide QC workflows because it tolerates complex mixtures, generates singly charged ions that are straightforward to interpret for peptides under approximately 10 kDa, and produces high-throughput results. Published analytical methods for synthetic peptide characterization have consistently used combined RP-HPLC and mass spectral analysis to confirm both purity and identity. A 1994 characterization of synthetic CCK-58, published in the Annals of the New York Academy of Sciences (Reeve et al., PMID 7514372, DOI: 10.1111/j.1749-6632.1994.tb44047.x), illustrates this standard approach: the synthetic peptide was characterized by isocratic and gradient RP-HPLC, amino acid analysis, mass spectral analysis, and sequence analysis, demonstrating that identity confirmation requires multiple orthogonal methods, not mass spectrometry alone.

On a CoA, the identity field typically reports: the theoretical molecular weight (calculated), the measured molecular weight (instrument result), and a pass/fail determination. Researchers should verify that the measured value is explicitly stated, a CoA that reports only “conforms” without providing the measured mass number offers no independent verification.

Purity: Reversed-Phase HPLC and What the Percentage Actually Measures

The purity percentage on a peptide CoA is a chromatographic area ratio, not a direct measure of the mass fraction of peptide in the vial. Reversed-phase HPLC (RP-HPLC) separates compounds in a mixture by their relative hydrophobicity as they travel through a nonpolar stationary phase (typically C18 or C8) eluted with an organic solvent gradient. A UV detector at 214–220 nm (which detects the peptide bond absorbance) records an absorbance trace; the area of each peak corresponds to the quantity of that compound passing through the detector.

Purity % = (area of target peptide peak) ÷ (total area of all peaks) × 100. A reported purity of ≥98% means that the target peptide accounts for at least 98% of the UV-absorbing material detected by the HPLC run. Impurities, deletion sequences, oxidation products, truncated fragments, residual protecting groups, account for the remaining area.

Published analytical chemistry literature confirms that RP-HPLC is the established primary method for purity assessment of synthetic peptides. A 2021 study by Sørensen et al. in ChemBioChem (PMID 33443297, DOI: 10.1002/cbic.202000826) demonstrated high-performance reversed-phase chromatography methods for purifying synthetic peptides and documented that RP-HPLC serves as both the purification platform and the primary purity assessment tool across diverse peptide sequences. A 2025 study by Yoshida et al. in the Journal of Chromatography A (PMID 39922152, DOI: 10.1016/j.chroma.2025.465748) further documented that standard RP-HPLC alone can mischaracterize impurity profiles for some cyclic peptides due to co-elution of chemically similar impurities, illustrating a genuine limitation of single-method purity reporting.

A 2023 study by Petersson et al. in the Journal of Chromatography A (PMID 36841023, DOI: 10.1016/j.chroma.2023.463874) developed two-dimensional LC-MS strategies specifically for peak purity assessment in pharmaceutical peptides, noting that isomers with the same mass are not differentiated by MS alone and must be resolved chromatographically, reinforcing why the combination of RP-HPLC (purity) plus mass spectrometry (identity) represents the current analytical standard.

Key interpretation point: A purity of ≥98% by HPLC does not mean the vial contains 98% peptide by weight. The weight fraction of peptide depends additionally on water content, counter-ion load, and other non-peptide mass, which is why the net peptide content field is a separate and equally important value.

Net Peptide Content: What Fraction of the Vial Is Actually Peptide

Net peptide content (also called “peptide content” or “peptide purity by weight”) is the gravimetric measurement of the actual peptide mass as a percentage of total vial weight. It answers the question that HPLC purity does not: of the total mass in this vial, what percentage is the target peptide compound?

The remainder consists of water (residual moisture from lyophilization), counter-ion salt (acetate or trifluoroacetate), and any excipients added during synthesis or formulation. A peptide supplied as its acetate salt form typically shows net peptide content in the range of 70–85%; a peptide in TFA (trifluoroacetate) salt form may show a lower net content because TFA has a higher molecular weight contribution per mole than acetate.

Net peptide content is measured by nitrogen-based quantitation. A 1996 paper by Bizanek, Manes, and Fujinari in Peptide Research (PMID 8727482) described RP-HPLC with chemiluminescent nitrogen detection (HPLC-CLND) specifically for this purpose, demonstrating a method that permits “universal quantitation of the peptide content of synthetic peptides” without requiring derivatization and free of interference from non-nitrogen-containing UV chromophores. The method directly measures the nitrogen distribution across HPLC peaks, enabling on-column quantitation of true peptide content rather than relying on UV response factors that vary by residue composition.

For researchers calculating working concentrations: if a vial is labeled 5 mg and the CoA reports 80% net peptide content, the actual peptide mass in the vial is approximately 4 mg (5 mg × 0.80). Failing to account for net peptide content when preparing research solutions will introduce systematic concentration errors that invalidate comparisons across experiments and across batches.

Moisture and Counter-Ion: The Non-Peptide Mass Components

Residual Moisture

Residual moisture is measured by Karl Fischer titration, a volumetric method that reacts water specifically with iodine in the presence of a base, allowing precise quantitation of water at the milligram-per-gram level. Lyophilized peptides retain some water even after freeze-drying; typical specifications for research-grade lyophilized peptides target less than 5–8% water by weight. Higher residual moisture content accelerates hydrolytic degradation of the peptide backbone and promotes microbial growth if the vial seal is compromised, and it directly contributes to the gap between total vial mass and net peptide mass.

Counter-Ion Identity and Load

Synthetic peptides produced by SPPS are isolated and purified as ionic salts. During RP-HPLC purification with standard gradients containing trifluoroacetic acid (TFA), the peptide is typically obtained as its trifluoroacetate (TFA) salt. TFA as a counter-ion is problematic for biological assays at elevated concentrations because TFA itself has documented cytotoxicity at concentrations relevant to in vitro systems. For this reason, a standard post-purification step in research-grade peptide manufacturing is ion exchange or buffer exchange to convert TFA salt to the acetate form, which is biologically inert at typical working concentrations.

The CoA should explicitly report both the identity of the counter-ion (acetate, TFA, chloride, or mixed) and the quantitative load (expressed as % by weight or molar equivalents). A CoA that states “acetate salt” without quantitation is preferable to TFA but still incomplete. Researchers running cell-based assays or in vivo models where counter-ion composition may matter should specifically check this field and request acetate-exchanged material when it is not confirmed.

The 2023 RP-HPLC study by Petersson et al. (PMID 36841023) specifically noted that TFA can form ion pairs with peptides and alter chromatographic selectivity, an illustration of why the counter-ion identity matters analytically as well as biologically.

Endotoxin: LAL Testing and Why It Matters

Endotoxins are lipopolysaccharides (LPS) derived from the outer membrane of Gram-negative bacteria. They are among the most potent biological contaminants in research systems because they activate innate immune pathways at extremely low concentrations, as low as picogram-per-mL levels in sensitive cell types, potentially confounding any assay involving immune cells, cytokine readouts, or in vivo rodent models. Endotoxin contamination does not originate from the peptide itself but from the water, glassware, reagents, and manufacturing environment used during synthesis, purification, and lyophilization.

The standard analytical method for endotoxin quantitation is the Limulus Amebocyte Lysate (LAL) assay, which exploits the clotting response of horseshoe crab (Limulus polyphemus) hemolymph extract to LPS. Results are reported in Endotoxin Units (EU) per mg or per mL. A 2016 review by Fennrich et al. in Alternatives to Laboratory Animals (PMID 27494624, DOI: 10.1177/026119291604400305) documented the history and current state of pyrogen detection methods, noting that the LAL test has been the gold-standard endotoxin detection method since the 1970s and remains the most widely applied test for parenteral pharmaceutical quality assurance.

A 2024 study by Schromm et al. in Biomedicine & Pharmacotherapy (PMID 38401515, DOI: 10.1016/j.biopha.2024.116286) described an important limitation of the LAL assay in complex formulations: the “low endotoxin recovery” (LER) effect, in which certain pharmaceutical formulations containing surfactants mask LPS aggregates and reduce LAL reactivity, potentially leading to falsely low endotoxin readings. Researchers evaluating CoA endotoxin values for peptide formulations containing excipients or surfactants should be aware of this methodological limitation.

Research-grade peptides without specific application requirements typically carry specifications of less than 1–5 EU/mg. Researchers running primary cell cultures, immune assays, or in vivo models should scrutinize this field carefully and consider the sensitivity of their specific assay system against the reported value.

Appearance: Visual Inspection and What to Look For

Physical appearance is assessed by visual inspection and is the simplest field on a CoA, yet it provides immediate first-pass information about a batch. A properly lyophilized, uncontaminated research peptide should appear as a white to off-white powder or fluffy cake with no visible discoloration. Yellowing or browning may indicate oxidative degradation (particularly of Trp-, Tyr-, or Met-containing sequences), Maillard reaction products from reducing sugars, or contamination. Pink or red coloration may suggest iron contamination or certain excipient reactions. Visible particulates, clumping, or oily residue inconsistent with a lyophilized solid are also red flags warranting further investigation before use.

Third-Party CoA vs. Vendor Self-Report: Evaluating the Source of the Data

Not all CoAs carry the same evidentiary weight. The critical distinction is between a CoA generated by an accredited independent analytical laboratory and one produced by the vendor’s own in-house QC operation (a vendor self-report). Understanding this distinction is essential for research quality control.

What a Legitimate Third-Party CoA Includes

A CoA issued by an accredited third-party laboratory, one operating under ISO 17025 accreditation or equivalent, provides several characteristics that a vendor self-report cannot replicate:

• Independent issuer identification: The document clearly identifies the testing laboratory as a separate legal entity from the peptide supplier, with the laboratory’s own name, address, accreditation number, and authorizing signature.
• Instrument and method identification: The specific analytical platform used (e.g., “Waters ACQUITY UPLC; C18 column; gradient 5–65% ACN/0.1% TFA; UV 214 nm”) is stated for each test. Method conditions allow independent replication or cross-validation.
• Raw data traceability: A batch number on the CoA should be traceable to laboratory records held by the testing laboratory, not only by the vendor.
• Accreditation statement: A legitimate third-party CoA typically includes a statement of the laboratory’s accreditation scope and, where applicable, references to the test methods used (e.g., “Endotoxin testing performed per USP <85> LAL method”).
• Date and signature: The date of testing and an authorized signatory at the testing laboratory are present.

Characteristics of a Vendor Self-Report to Recognize

A vendor self-report is a document generated by the same organization that manufactured and sold the peptide. This creates a fundamental conflict of interest in quality reporting. Common characteristics include: the issuing organization name matches the vendor name; no independent laboratory is identified; method details are absent or generic (“HPLC” without column, gradient, or wavelength); no accreditation statement; and no independently traceable batch records. Vendor self-reports are not fabrications by definition, many vendors do conduct real analytical testing, but they cannot be independently verified and do not carry the same research quality standing as third-party documentation.

Red Flags on a Peptide CoA: What Warrants Further Scrutiny

The following CoA characteristics should prompt additional evaluation before a compound is used in research:

• Missing fields: Any CoA that omits identity (mass), purity (HPLC %), or net peptide content is analytically incomplete.
• No raw values for mass spec: “Identity: conforms” without a measured molecular weight provides no independent verification of identity.
• Purity reported without method details: “Purity: 99%” without column, mobile phase, and wavelength cannot be compared across batches or independently reproduced.
• No endotoxin data: Particularly concerning for cell-based or in vivo research applications where LPS contamination would directly confound results.
• TFA counter-ion not disclosed: If counter-ion is unlisted and the purification method used TFA (the standard), TFA contamination should be assumed until ruled out.
• Issuer not independently identifiable: A CoA where no testing laboratory can be identified or contacted for records verification cannot be independently validated.
• Batch number mismatch: The batch number on the CoA should match the batch number printed on the vial. Any discrepancy means the document may not describe the material in hand.

How Researchers Use CoA Data for Experimental Quality Control

A CoA is most useful when incorporated systematically into research documentation rather than reviewed once and set aside. The following framework represents standard practice for maintaining analytical traceability in peptide research workflows:

• File the CoA with the batch record: Every vial used in research should be traceable to a CoA document retained in the lab’s records. If a result cannot be explained, the CoA provides a starting point for investigating whether compound quality was a variable.
• Use net peptide content to calculate true concentration: All stock solutions and working dilutions should be based on the net peptide content percentage, not nominal vial weight, to ensure concentration accuracy across experiments.
• Cross-reference batch numbers across experiments: If results differ between experimental runs that used different batches of the same peptide, comparing the CoA values for those batches (purity, content, endotoxin) can help identify a material variable.
• Set application-specific endotoxin thresholds: Endotoxin specifications should be defined before sourcing material, based on the sensitivity of the assay system and the cell types involved, not evaluated after results are in hand.
• Document the CoA source: Recording whether a CoA is third-party or vendor-issued is part of the research record and is relevant to how much weight should be placed on the analytical values it reports.

Frequently Asked Questions About Peptide Certificates of Analysis

What is a Certificate of Analysis (CoA) for a synthetic peptide?

A Certificate of Analysis (CoA) is an analytical document that summarizes the results of quality-control testing performed on a specific batch of synthetic peptide. A complete CoA for a research-grade peptide typically includes identity confirmation by mass spectrometry, purity by reversed-phase HPLC, net peptide content by nitrogen-based quantitation, residual moisture, counter-ion identity and load, endotoxin level by LAL assay, and physical appearance. Each field is generated by a distinct analytical method and answers a different question about the compound.

What does HPLC purity mean on a peptide CoA?

HPLC purity is the percentage of the UV chromatogram area attributed to the target peptide peak during a reversed-phase HPLC run. A value of ≥98% means that 98% of the UV-absorbing material detected by the instrument is the target compound; the remaining area represents impurities such as deletion sequences, truncated fragments, or oxidation products. HPLC purity does not directly measure the mass fraction of peptide in the vial, that is reported separately as net peptide content.

What is the difference between HPLC purity and net peptide content?

HPLC purity is a chromatographic area ratio; net peptide content is a gravimetric measure. A vial may show ≥98% HPLC purity, meaning the compound is analytically pure by chromatographic standards, but still have a net peptide content of only 75–80% because the remaining 20–25% of total vial weight consists of water, acetate counter-ion, and residual salts. Both values are required to calculate accurate research concentrations; using nominal vial weight instead of net peptide content introduces systematic concentration errors.

What endotoxin level is acceptable on a research peptide CoA?

Acceptable endotoxin levels depend on the downstream research application. USP standards for injectable pharmaceuticals require <0.2 EU/mL (intrathecal) or <5 EU/kg/hr (systemic parenteral). For general research-grade peptides, many suppliers specify <1–5 EU/mg. Endotoxin is measured by the Limulus Amebocyte Lysate (LAL) assay. Researchers running primary cell cultures, immune assays, or in vivo rodent experiments should define acceptable endotoxin thresholds based on the sensitivity of their specific assay system before evaluating CoA values against those thresholds.

For educational and research reference purposes only. Not medical advice. Not for human use.

TL;DR: Aseptic technique is the set of laboratory practices that prevents microbial, endotoxin, and particulate contamination of research samples. In peptide research, maintaining sample sterility is not a secondary concern, it is a prerequisite for data validity. Bacterial contamination introduces proteolytic enzymes that degrade the compound; endotoxin contamination introduces biological confounders that can independently drive assay responses attributed to the peptide. This article covers contamination sources, clean-technique fundamentals (laminar flow, surface preparation, vial/septum handling), why bacteriostatic water differs from sterile water for multi-draw sample preservation, and how contamination propagates through a research dataset to invalidate findings.

Research-Use Disclaimer: This article is for educational and research methodology reference purposes only. It describes laboratory practices for maintaining the integrity of research samples as chemical reagents. Nothing in this article constitutes medical advice, dosing guidance, or instructions for human use of any compound. All content describes practices for handling research samples in a controlled laboratory setting. For adults 21+ with a research interest only.

What Is Aseptic Technique and Why Does Sample Integrity Depend on It?

Aseptic technique is a foundational concept in microbiology and pharmaceutical science: a collection of laboratory practices designed to exclude microorganisms, their metabolic products (such as endotoxins), and particulates from samples, solutions, and reagents during handling. The term “aseptic” is derived from the Greek prefix a- (without) and sepsis (putrefaction or microbial contamination), meaning, literally, working in a manner that prevents contamination from occurring in the first place.

In the context of peptide research, aseptic technique is not merely a safety practice in the colloquial sense, it is a data validity practice. A reconstituted peptide solution is a chemically defined reagent. The moment environmental microorganisms, fungal spores, or endotoxins are introduced into that solution, its identity changes: it is no longer a defined sample of compound X at concentration Y, but an undefined mixture of compound X, microbial metabolites, bacterial cell wall fragments, and proteolytic enzymes. Results obtained from such a sample cannot be confidently attributed to the intended compound.

A 2020 protocol by Bykowski and Stevenson, published in Current Protocols in Microbiology, formally describes aseptic technique as the set of laboratory procedures “that can reduce the risk of culture contamination, ” and identifies two major strategic approaches documented in standard microbiology practice: working with a Bunsen burner flame to create a localized convection barrier to airborne particles, and working within a laminar flow hood that provides HEPA-filtered unidirectional airflow. The protocol covers pipetting, dispensing aliquots, preparing media, and inoculating cultures, procedures that map directly onto the operations a researcher performs when handling reconstituted peptides. (PubMed PMID: 32150342)

Sources of Contamination in Peptide Research Settings

Understanding contamination requires identifying its sources, because each source type requires a different mitigation strategy, and failing to control even one can undermine all others.

Airborne Microbial and Particulate Contamination

Standard laboratory air contains bacteria, fungal spores, dust particles, and skin cells shed by occupants. These particles are suspended in turbulent airflow and settle onto open surfaces, uncapped vials, and exposed solutions over time. The density of airborne contamination varies with room traffic, ventilation design, and surface disturbance (talking, moving quickly, sneezing). In an uncontrolled bench environment, even a briefly uncapped vial can accumulate viable microorganisms from the ambient air.

The primary defense against airborne contamination in research laboratories is a laminar flow biosafety cabinet or clean bench. These enclosures draw laboratory air through HEPA (High-Efficiency Particulate Air) filters, rated to capture ≥99.97% of particles ≥0.3 µm in diameter, which encompasses bacteria (typically 0.5–5 µm) and most fungal spores. The filtered air is delivered as a unidirectional laminar stream across the work surface, preventing ambient room air from reaching the work area. Horizontal laminar flow hoods direct filtered air from back to front, sweeping contaminants away from the sample toward the operator; vertical flow cabinets direct air downward and are the standard for biological safety cabinet (BSC) Class II configurations.

Researcher-Borne Contamination

The researcher is frequently the dominant contamination source in laboratory work. The human body surface continuously sheds skin cells, bacteria resident on the skin microbiome, and respiratory droplets containing oral and nasal flora. Working without gloves transfers skin bacteria directly to vials, syringes, and surfaces. Talking, coughing, or breathing over open containers deposits respiratory aerosols. Hair follicles and eyebrows shed debris.

Standard practices to control researcher-borne contamination include: wearing nitrile or latex gloves (changed between tasks and after touching non-sterile surfaces); wearing a lab coat that covers the arms; keeping hair tied back or covered; working with the face directed away from open containers; not talking, coughing, or sneezing over open samples; and, critically, keeping all open-vial work within the airflow-controlled zone of the laminar flow hood rather than on an open bench.

Surface and Equipment Contamination

Bench surfaces, equipment exteriors, and container exteriors are not sterile. They accumulate environmental microorganisms, particulates, and residues from prior use. Any item brought into the aseptic work zone that has not been decontaminated becomes a contamination source.

Decontamination of work surfaces prior to beginning sample handling typically involves wiping all surfaces with 70% isopropyl alcohol (IPA), effective against most bacteria and many fungi and viruses, and allowing the alcohol to fully evaporate before placing samples or reagents on the surface. This sequence is important: pooled IPA that contacts a solution can alter its chemistry, so the alcohol must dry completely. Within a laminar flow hood, the interior work surfaces and walls should be wiped with 70% IPA before each session.

Endotoxin: The Invisible Contamination Problem

Endotoxins, specifically lipopolysaccharides (LPS) from the outer membrane of Gram-negative bacteria, represent a particularly important contamination category in peptide research because they persist even after the bacteria that produced them are killed. Standard sterilization procedures (heat, filtration, alcohol wiping) can eliminate viable bacteria while leaving endotoxins intact. Autoclave sterilization kills bacteria but does not reliably destroy LPS, which is heat-stable at standard autoclave temperatures for short cycles.

The research significance of endotoxin contamination is substantial: LPS is one of the most potent activators of mammalian immune cells in vitro, triggering cytokine release (TNF-α, IL-1β, IL-6) through TLR4 (Toll-like Receptor 4) signaling at picogram-per-mL concentrations. In a cell-based peptide assay, nanogram quantities of endotoxin contamination can independently drive inflammatory responses that would be incorrectly attributed to the peptide compound under study.

A 2010 review by Dubczak and colleagues in the International Journal of Pharmaceutical Compounding specifically addresses the need for endotoxin testing in compounded sterile preparations, noting that “inadvertent exposure to endotoxins… can cause a constellation of adverse effects” and that compounders of sterile formulations “must remain exceptionally vigilant to guard against the contamination of such preparations with those pyrogens.” (PMID: 23965585) While that context is pharmaceutical compounding, the underlying principle applies equally to research sample handling: endotoxin-contaminated samples produce invalid biological data.

Depyrogenation, the removal of endotoxins from surfaces or solutions, requires methods distinct from sterilization: dry heat at ≥250°C for ≥30 minutes (for heat-stable glassware), treatment with 1 M NaOH, or use of certified depyrogenated labware. For research solutions, the most reliable approach is to start with certified endotoxin-free reagents and use clean technique throughout to prevent bacterial contamination that would generate endotoxins in situ.

Clean-Technique Fundamentals: Surfaces, Laminar Flow, and Vial Handling

The operational practices of aseptic technique can be organized into three interlocking categories: preparation of the work environment, management of air and contamination barriers, and direct handling of vials, septa, and transfer equipment.

Preparing the Work Environment

Before any sample handling begins, the work environment should be established in a defined sequence:

1. Select the appropriate clean zone. A laminar flow hood or biological safety cabinet is the preferred environment. If one is unavailable, working in proximity to a lit Bunsen burner creates a localized updraft that reduces particle settling near the flame, a traditional technique documented in standard microbiology protocols.
2. Decontaminate all surfaces. Wipe the interior of the laminar flow hood, working surface, side walls, and back wall, with 70% IPA. Allow to dry completely before placing any materials inside.
3. Run the laminar flow hood for the required equilibration time. Most laminar flow hoods require 5–15 minutes of operation before the HEPA-filtered airflow establishes a stable laminar profile throughout the enclosure. Beginning work immediately after activating the unit may not provide full contamination protection.
4. Organize materials before starting. All materials needed for the session, vials, syringes, alcohol wipes, pipettes, should be arranged in the hood before opening any sample, minimizing unnecessary reaching across open containers and reducing the turbulence that disrupts laminar flow.
5. Don gloves. Put on fresh gloves after decontaminating the hood and immediately before work begins. Gloves that have touched the exterior of the hood, bench surfaces, or any non-sterile surface should be changed before touching sample containers.

Laminar Flow Discipline

Working in a laminar flow hood correctly requires understanding the direction of air movement and organizing work to take advantage of it. In a horizontal laminar flow hood, air moves from the HEPA filter at the back toward the operator at the front. This means:

• Open samples and sterile items should be positioned toward the back of the hood (closest to the filter), where the air is cleanest and flows directly over them toward the front, rather than across contaminated surfaces first.
• Avoid blocking the airflow with large items or with the researcher’s arms, which disrupt the laminar profile and create turbulent eddies that allow room air to penetrate.
• Do not place non-sterile items upstream (toward the filter side) of sterile items. This would allow the airflow to carry contaminants from the non-sterile item over the sterile sample.
• Minimize unnecessary movement inside the hood. Rapid arm movements disrupt the laminar air profile, potentially introducing room air into the work zone.

The importance of proper laminar flow hood use for maintaining sample sterility is demonstrated in the compounding pharmacy literature. A 2018 study by Huang et al. in Peritoneal Dialysis International compared sterility outcomes of fluid admixtures prepared by trained personnel using a non-touch aseptic technique (NTAT) versus preparation in a sterile suite, finding that sterility was maintained in all tested preparations regardless of whether a formal sterile suite or a trained non-touch technique was used, provided procedural discipline was consistently applied. (PMID: 29311196) The finding underscores that technique discipline, not simply equipment, is the operative variable.

Vial and Septum Handling

The vial septum, the rubber stopper through which a needle is inserted to access the contents, is the primary point at which contamination is introduced into a reconstituted sample. Correct septum handling practice involves the following documented steps:

Alcohol wipe and dry

Before each needle insertion, wipe the septum surface with a 70% isopropyl alcohol swab using a single stroke (not back-and-forth, which can redeposit organisms). Allow the alcohol to dry completely, typically 10–30 seconds. Inserting a needle through wet alcohol introduces alcohol residue into the sample.

Avoid coring

Insert the needle bevel-up at a slight angle, then straighten to vertical. This technique minimizes the probability of “coring”, removing a small plug of rubber from the septum with the needle tip and depositing it as a particulate into the solution.

Single-use needles

Each needle insertion should use a fresh, sterile needle. A needle that has been used once has a compromised tip geometry and has contacted the solution interior; reuse introduces both dulled metal particles and any organisms that colonized the exposed hub during the interval between uses.

Do not leave needles in place

A needle left in the septum between uses creates a continuous pathway through which environmental air and organisms can access the vial interior. All needles should be removed and the septum re-wiped before any period between draws.

Inspect the septum

Before each use session, inspect the septum visually. Coring damage, cracking, or discoloration indicates septum compromise and may warrant discarding the vial in favor of sample integrity.

Bacteriostatic vs. Sterile Water: What the Distinction Means for Sample Preservation

The choice of reconstitution solvent has direct implications for sample contamination risk, particularly when a vial will be accessed multiple times across a research session or across sessions.

Sterile Water for Injection (SWFI)

Sterile water for injection is water that has been sterilized, by filtration through a 0.22 µm membrane, by autoclaving, or both, and packaged in a sealed container. It contains no antimicrobial additives. Its sterility is guaranteed at the point of first opening, but once the septum is punctured, the vial interior can be colonized by any organisms introduced through the access point. In a single-draw scenario, where the entire volume is withdrawn at once, this is not a meaningful concern. In a multi-draw scenario, each subsequent needle insertion carries contamination risk, and without a bacteriostatic agent, any organisms introduced can proliferate in the aqueous solution between draws.

Bacteriostatic Water for Injection (BWFI)

Bacteriostatic water for injection contains 0.9% benzyl alcohol (w/v) as a preservative. Benzyl alcohol functions as a bacteriostatic agent, meaning it inhibits the multiplication of bacteria introduced into the solution, without necessarily killing all organisms on contact. The mechanism involves disruption of bacterial cell membrane integrity, reducing the viable organism count and preventing the explosive proliferation that would otherwise occur in an aqueous environment at laboratory temperatures.

For research applications where a reconstituted peptide vial will be accessed across multiple sessions, bacteriostatic water provides a meaningful additional layer of protection against microbial multiplication between uses. A 2013 study by Caritis et al. in the American Journal of Obstetrics and Gynecology evaluated compounded formulations with and without benzyl alcohol as a preservative over a 19-week period, finding that formulations containing benzyl alcohol remained microbe- and pyrogen-free throughout the study period, while the no-preservative conditions showed comparable sterility only under controlled single-use-like conditions. (PMID: 23453884) The practical implication for research sample handling is clear: for multi-draw vials, bacteriostatic water’s preservative function supplements, but does not replace, aseptic technique.

When Sterile Water Is Appropriate

Sterile water is the appropriate solvent when a sample will be used in a single session with the entire volume withdrawn at once, when the experimental context requires the absence of any additive (including benzyl alcohol), or when working with compounds for which benzyl alcohol compatibility is a consideration based on the compound’s specific chemical properties. In these cases, stringent aseptic technique during reconstitution and immediate use are the primary contamination controls.

How Contamination Invalidates Research Data

The consequences of contamination for research validity extend beyond the obvious scenario of a visibly turbid vial. Three mechanisms through which contamination corrupts research data are particularly important to understand:

Compound Degradation by Proteolytic Enzymes

Bacteria that colonize a peptide solution produce extracellular proteases, enzymes that cleave peptide bonds, as part of their normal metabolic activity. These enzymes act on the research peptide in solution, progressively reducing the concentration of intact compound and producing degradation fragments of unknown activity. A researcher who reconstitutes a peptide at 1 mg/mL and uses it over three days without adequate contamination control may be measuring the effects of 0.7 mg/mL of intact compound, 0.1 mg/mL of unknown fragments, and 0.2 mg/mL of degradation products, a mixture that does not represent the intended experimental condition. Results from this experiment are not reproducible and cannot be accurately compared to results from a clean sample.

Endotoxin as an Independent Biological Confounder

As noted above, bacterial endotoxins are potent activators of innate immune signaling pathways at very low concentrations. In any cell-based or in vitro assay that involves immune cells, endothelial cells, or cells expressing pattern recognition receptors, endotoxin contamination will independently drive outputs, cytokine production, gene expression changes, cell death, that cannot be distinguished from the peptide’s own effect without systematic controls. Published reviews of outbreak events linked to contaminated compounded sterile preparations, including a 2018 analysis by Shehab et al. in the Journal of Patient Safety examining 19 outbreak events resulting in over 1, 000 cases, consistently identify “breaches in aseptic processing and deficiencies in sterilization procedures or in sterility/endotoxin testing” as the common factor. The review found that contamination-related events were most commonly linked to non-adherence to sterile preparation standards, a pattern that applies as directly to research sample handling as to clinical compounding. (PMID: 26001553)

Irreproducibility and Dataset Corruption

A contaminated batch of reconstituted sample, used across multiple experiments before the contamination is detected (if it is detected at all), introduces systematic error into the dataset. Experiments run on the contaminated sample will produce internally consistent results, which may appear convincing, but those results will not replicate when a clean sample is prepared. If the contamination varies across batches (which is typical, because microbial growth is stochastic), different experiments will be contaminated to different degrees, producing variable results that appear to show high biological variability in the compound’s effects when the variability is actually in the contamination level. This type of systematic error is among the most difficult to identify retrospectively.

The logical consequence is that aseptic technique cannot be treated as optional or secondary to experimental design: it is a component of experimental design. Every reconstitution event, every draw from a vial, every transfer between containers is an opportunity for contamination that, if it occurs, may render hours or weeks of experimental work uninterpretable.

Frequently Asked Questions About Aseptic Technique in Peptide Research

What is aseptic technique in a laboratory context?

Aseptic technique refers to a set of laboratory practices designed to prevent microbial, endotoxin, and particulate contamination of samples and reagents. In peptide research, two primary clean-work strategies are documented in the microbiology literature: working in proximity to a Bunsen burner flame (creating a convection barrier to airborne particles) and working within a laminar flow hood (a controlled-environment enclosure providing HEPA-filtered unidirectional airflow). Both approaches reduce the probability that environmental microorganisms will contact an open vial or solution during handling.

Why does contamination matter for peptide research sample validity?

Microbial or endotoxin contamination of a reconstituted peptide sample can confound assay results in multiple ways: bacteria produce proteolytic enzymes that degrade the compound, reducing its effective concentration; bacterial endotoxins (lipopolysaccharides) are potent immune activators that can independently trigger biological responses in cell-based assays, producing results attributed to the peptide that are actually caused by the contaminant. A contaminated sample can yield false positive or false negative findings that corrupt the research record and prevent reproducibility.

What is the difference between bacteriostatic water and sterile water for sample reconstitution?

Sterile water for injection (SWFI) is sterilized water with no additives, it supports microbial growth if organisms are introduced after opening. Bacteriostatic water for injection (BWFI) contains 0.9% benzyl alcohol, which inhibits bacterial proliferation. For multi-draw research applications where the same vial is accessed across sessions, bacteriostatic water provides an additional layer of protection against microbial multiplication between uses, complementing (not replacing) aseptic technique at each draw. For single-draw use or applications requiring no additive, sterile water is appropriate with strict clean technique.

What vial and septum handling practices protect sample sterility?

Key practices include: wiping the septum with 70% isopropyl alcohol before each needle insertion and allowing it to dry fully; using a fresh sterile needle for each draw; inserting the needle bevel-up at a shallow angle to minimize coring of septum material into the solution; removing all needles between uses rather than leaving them in place; and inspecting the septum visually for coring damage or cracks before each use session. These steps collectively limit contamination introduced through the septum penetration point, the primary access route into a closed vial.

For educational and research reference purposes only. Not medical advice. Not for human use.

TL;DR: BPC-157 and TB-500 are both Tier 2 preclinical peptides studied in rodent tissue-repair models, but they operate through distinct primary mechanisms. BPC-157 (a synthetic 15-amino acid gastric peptide) acts via modulation of the VEGF/angiogenesis axis and the nitric oxide system. TB-500 (a fragment derived from Thymosin beta-4) acts primarily through G-actin sequestration, regulating cytoskeletal dynamics and cell migration. Neither is FDA approved, neither has human RCT data for tissue repair, and both are prohibited by WADA, under different sections.

Research-Use Disclaimer: This article is for educational and research reference purposes only. BPC-157 and TB-500 are research compounds not approved by the FDA for human use. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published preclinical research. For adults 21+ with a research interest only.

Quick-Reference Comparison: BPC-157 vs TB-500

What Is BPC-157 and What Is Its Primary Mechanism?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide, a 15-amino acid chain (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), derived from a protein isolated in human gastric juice. Unlike TB-500, which maps to a defined region of a known structural protein, BPC-157 is a partial sequence of the gastric protein BPC that was selected for preclinical study on the basis of its stability and activity profile.

The compound does not appear to operate via a single receptor target. Researchers at the University of Zagreb, who have generated the majority of published BPC-157 literature, describe it as a pleiotropic agent documented across multiple interacting biological systems. Two mechanisms are most consistently cited across independent research groups.

BPC-157 Mechanism 1: VEGF Modulation and Angiogenesis

Based on articles retrieved from PubMed, a 2018 review by Seiwerth et al. in Current Pharmaceutical Design systematically compared BPC-157 against standard angiogenic growth factors (EGF, FGF, VEGF), concluding that BPC-157 was the only agent consistently effective across all tested acute and chronic gastrointestinal injury models as well as tendon, ligament, muscle, and bone healing models (PMID: 29998800). The review characterizes BPC-157 as a context-sensitive angiogenic modulator rather than a direct growth-factor mimic, it upregulates VEGF expression in the presence of active injury, rather than constitutively.

A 2015 study by Huang et al. (Fourth Military Medical University) in Drug Design, Development and Therapy examined BPC-157 in an alkali burn rat model and in human umbilical vein endothelial cell (HUVEC) cultures, finding that BPC-157 upregulated VEGF-a expression, accelerated vascular tube formation in vitro, and regulated ERK1/2 phosphorylation along with downstream targets c-Fos, c-Jun, and Egr-1, key molecules in cell growth, migration, and angiogenesis (PMID: 25995620). This study is notable as one of the few BPC-157 reports from a research group independent of the Zagreb laboratory.

BPC-157 Mechanism 2: Nitric Oxide System Interaction

A defining mechanistic feature of BPC-157 in the literature is its documented interaction with the nitric oxide system. The compound’s effects have been characterized as closely participatory in the NO system’s homeostatic healing response, with interactions documented for both NOS pathway regulation and downstream NO-mediated cytoprotection. A 2022 review by Vukojevic et al. in Neural Regeneration Research extended this to the CNS context, documenting BPC-157’s counteraction of L-NAME-induced catalepsy, schizophrenia-like symptoms, and stroke-induced neuronal damage in rodent models, effects attributed to NO system modulation and dopaminergic pathway interaction (PMID: 34380875).

BPC-157 Research Breadth: Soft Tissue and Gastrointestinal Models

A 2019 review by Gwyer, Wragg, and Wilson at Loughborough University in Cell and Tissue Research, an independent, non-Zagreb assessment, noted that all published studies investigating BPC-157 demonstrated consistently positive healing effects for various injury types across soft tissues including tendon, ligament, and skeletal muscle, while also observing that the majority of studies were conducted on small rodent models by a limited number of research groups (PMID: 30915550). A 2021 review by Seiwerth et al. in Frontiers in Pharmacology generalized wound healing findings across skin, gastrointestinal, tendon, ligament, bone, and corneal tissue in rat models, noting that BPC-157 was previously employed in two human clinical trials for ulcerative colitis and multiple sclerosis with no reported toxicity (PMID: 34267654).

What Is TB-500 and What Is Its Primary Mechanism?

TB-500 is the commercial name for a synthetic peptide fragment corresponding to amino acids 17–23 of Thymosin beta-4 (Tβ4), a 43-amino acid protein found in virtually all mammalian nucleated cells. The sequence of the commercial product is Ac-LKKTETQ (N-terminally acetylated). This region was selected because it corresponds to the actin-binding domain of the parent protein.

An important distinction governs all TB-500 evidence assessment: the published scientific literature is built almost entirely around full-length Thymosin beta-4, not the commercial TB-500 fragment. The mechanistic rationale for TB-500 is an extrapolation from Tβ4 biology, coherent but not independently validated to the same depth.

TB-500 / Tβ4 Mechanism: G-Actin Sequestration

The foundational mechanism of Thymosin beta-4 is its role as the primary G-actin sequestering protein in mammalian cells. Actin exists in two forms: G-actin (globular, monomeric, unpolymerized) and F-actin (filamentous, polymerized). Tβ4 binds G-actin with micromolar affinity, maintaining a readily available but unpolymerized pool. When cells receive wound or migration signals, this sequestered pool releases and polymerizes rapidly, enabling cytoskeletal reorganization.

Based on articles retrieved from PubMed, a 2012 review by Goldstein, Hannappel, Sosne, and Kleinman in Expert Opinion on Biological Therapy, a landmark summary of Tβ4 biology, documents that after injury, Tβ4 is released by platelets, macrophages, and other cell types to protect cells and tissues from further damage, reduce apoptosis and inflammation, bind to actin, and promote cell migration, including the mobilization, migration, and differentiation of stem/progenitor cells that form new blood vessels and regenerate tissue; Tβ4 also decreases myofibroblast numbers in wounds, reducing scar formation and fibrosis (PMID: 22074294).

TB-500 / Tβ4 Research Contexts: Wound, Corneal, and Cardiac Models

A foundational 1999 study by Malinda, Goldstein, Kleinman, and colleagues at the NIH in Journal of Investigative Dermatology demonstrated that topical or intraperitoneal Tβ4 treatment in a rat full-thickness wound model increased reepithelialization by 42% over saline controls at 4 days and by 61% at 7 days post-wounding, with increased collagen deposition, angiogenesis, and 2–3-fold stimulation of keratinocyte migration in the Boyden chamber assay (PMID: 10469335). This is among the most frequently cited foundational Tβ4 wound healing studies.

A 2010 review by Philp and Kleinman (NIH/NIDCR) in Annals of the New York Academy of Sciences reviewed animal model evidence across dermal, corneal, and cardiac wound repair, concluding that Tβ4 studies in various animal models of disease and repair have provided the scientific foundation for ongoing clinical trials in dermal, corneal, and cardiac wound repair, representing an explicit statement that preclinical evidence was sufficient to advance to human clinical trials in those specific contexts (PMID: 20536453).

Corneal repair represents the furthest-advanced clinical translation of Tβ4. A 2018 review by Sosne in Expert Opinion on Biological Therapy traced the arc from bench to clinical trial, noting that Tβ4 has entered Phase 3 human clinical trials for dry eye disease and neurotrophic keratopathy, the most advanced human clinical development of any Tβ4-related compound (PMID: 30063853). This Phase 3 data pertains to the full-length Tβ4 protein in an ocular context, not the commercial TB-500 fragment in musculoskeletal applications.

A 2015 review by Goldstein and Kleinman in Expert Opinion on Biological Therapy synthesized the broader preclinical-to-clinical picture, concluding that Tβ4 has been used successfully in several clinical trials involving tissue repair and regeneration, with significant advances in understanding its direction of stem cell maturation following injury, providing the scientific foundation for ongoing and projected trials in eye injuries, dermal wounds, cardiac repair following myocardial infarction, and brain healing following stroke (PMID: 26096726).

How BPC-157 and TB-500 Differ at the Mechanism Level

The distinction between these two compounds is mechanistically fundamental, not merely pharmacological. They address different biological bottlenecks in the tissue-repair cascade:

BPC-157 appears to operate primarily at the level of vascular signaling and cytoprotective gene expression. Its documented activity involves upregulating VEGF in injured tissue, interacting with NO signaling to modulate vasoprotection and hemostasis, and influencing ERK1/2-mediated proliferation pathways. The compound is described as “pleiotropic” in part because its interactions touch multiple signaling cascades rather than a single defined receptor. It does not have a characterized actin-binding function in the published literature.

TB-500 / Tβ4 operates upstream of the cytoskeletal machinery that drives cell movement itself. By sequestering G-actin, Tβ4 regulates the pool from which filamentous actin is polymerized, the fundamental substrate of cellular locomotion. This mechanism is cell-intrinsic and does not depend on extracellular vascular signaling to initiate its primary action. The downstream effects on migration, angiogenesis, and wound closure are consequences of enabling faster and more coordinated cell movement in response to injury signals.

Both compounds have been studied in overlapping research contexts, wound healing, tendon/soft tissue injury, and gastrointestinal models, and both have documented associations with angiogenesis. However, the angiogenic activity attributed to BPC-157 is framed as a direct modulatory effect on VEGF expression, while the angiogenic activity attributed to Tβ4 is largely a downstream consequence of its role in endothelial cell migration.

What the Research Shows: Evidence by Tier

BPC-157 Evidence Summary

TB-500 / Tβ4 Evidence Summary

WADA Classification: Why the Two Sections Differ

Researchers and compliance-focused audiences should note that the two compounds are prohibited under different WADA sections, and the distinction is not arbitrary. BPC-157 falls under Section S0: Non-Approved Substances, the broadest prohibition category, covering any pharmacological substance not approved by any governmental regulatory authority for human therapeutic use. BPC-157 has no approved therapeutic indication anywhere in the world.

TB-500 and Thymosin beta-4 are prohibited under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. This section targets peptide growth factors and their mimetics specifically, reflecting WADA’s classification of Tβ4 as a substance with potential performance-enhancing effects via its growth factor-related biology. Both prohibitions apply in-competition and out-of-competition. Athletes in sanctioned sports should treat either compound as prohibited regardless of administration route or stated purpose.

Frequently Asked Questions: BPC-157 vs TB-500

What is the difference between BPC-157 and TB-500?

The core mechanistic difference is one of molecular target. BPC-157 is a synthetic 15-amino acid gastric peptide primarily documented to modulate the VEGF/angiogenesis axis and the nitric oxide system in rodent injury models. TB-500 is a synthetic fragment derived from Thymosin beta-4 whose parent protein’s primary documented mechanism is G-actin sequestration, regulating the cytoskeletal dynamics that drive cell migration during wound response. Both are Tier 2 preclinical compounds: substantial animal model data, no human RCT data for tissue repair, not FDA approved, and prohibited by WADA.

Are BPC-157 and TB-500 both prohibited by WADA?

Yes. BPC-157 is prohibited under WADA Section S0 (Non-Approved Substances). TB-500 and Thymosin beta-4 are prohibited under WADA Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Both prohibitions apply in-competition and out-of-competition. The different sections reflect their different pharmacological classifications, not a difference in prohibition severity, both are fully prohibited for athletes subject to WADA-compliant anti-doping programs.

What evidence tier do BPC-157 and TB-500 share?

Both are Tier 2 compounds in the Legendary Labz framework: multiple peer-reviewed animal model studies with consistent mechanistic findings, but lacking the human randomized controlled trial evidence required for Tier 1 classification. An important sub-distinction: TB-500 as a specific commercial fragment carries an additional caveat, most of the supporting literature is for full-length Thymosin beta-4, not the truncated Ac-LKKTETQ fragment marketed as TB-500. BPC-157 has more direct published research on the actual compound used.

Does BPC-157 or TB-500 have more independent published research?

BPC-157 has a larger body of research studying the compound directly, though the majority originates from a single academic laboratory (University of Zagreb). An independent 2019 review from Loughborough University (Gwyer et al.) assessed the BPC-157 literature, and a 2015 Chinese group (Huang et al.) published an independent in vitro and animal study. TB-500’s mechanistic foundation rests on the Thymosin beta-4 literature, which is broader and involves multiple independent research groups including NIH-affiliated investigators, but the specific commercial fragment has almost no independent efficacy research of its own.

For educational and research reference purposes only. Not medical advice. Not for human use.

TL;DR: Thymosin Alpha-1 (thymalfasin, trade name Zadaxin) is a synthetic 28-amino acid peptide originally isolated from bovine thymus, studied extensively for its role as an immune modulator. Acting through Toll-like receptor (TLR) signaling, dendritic cell activation, and Th1 polarization, it is one of the most clinically studied thymic peptides in existence, with regulatory approval as a drug in more than 35 countries for hepatitis B and C, and ongoing investigation in sepsis, cancer adjuvant contexts, and infectious disease. It is not approved by the U.S. FDA for any therapeutic use, and in 2023 the FDA specifically restricted its compounding.

Research-Use Disclaimer: This article is for educational and research reference purposes only. Thymosin Alpha-1 (thymalfasin) is a research compound in the United States context. Where approved as a prescription drug in other jurisdictions, it is available only under licensed medical supervision. This content does not constitute medical advice, does not recommend or endorse human self-administration of any compound, and does not describe personal-use protocols. All study findings described below refer to published literature. For adults 21+ with a research interest only.

What Is Thymosin Alpha-1? Definition, Origins, and Regulatory Context

Thymosin Alpha-1, abbreviated Tα1, also written thymosin alpha-1, thymalfasin, or by its trade name Zadaxin, is a synthetic 28-amino acid polypeptide whose sequence was originally isolated from thymosin fraction 5, a bovine thymus extract. The peptide corresponds to amino acids 1–28 of prothymosin alpha, a protein found in abundance in the thymic microenvironment where T-cell maturation occurs.

The compound’s development was led by SciClone Pharmaceuticals, which commercialized it under the trade name Zadaxin. As documented in a 2002 review by Billich in Current Opinion in Investigational Drugs, thymalfasin was approved and launched in Argentina, China, Peru, the Philippines, Singapore, Thailand, Mexico, Venezuela, and multiple other countries for the treatment of chronic hepatitis B virus (HBV) infection, with approval subsequently expanded to include hepatitis C virus (HCV) infection in several markets; the compound also entered Phase III trials in the United States in combination with PEGylated interferon-alpha and was being investigated for non-small cell lung cancer, hepatocellular carcinoma, AIDS, and malignant melanoma (PMID: 12090542).

A note on naming confusion: despite sharing “thymosin” in its name, Thymosin Alpha-1 is entirely unrelated to TB-500 or Thymosin beta-4. The two peptides differ in sequence, structure, target biology, mechanism, and clinical history. See the TB-500 compound profile for details on the beta-4 family.

What Are the Documented Mechanisms of Thymosin Alpha-1?

Thymosin Alpha-1 does not operate through a single receptor or pathway. The published research characterizes it as a pleiotropic immune modulator acting at multiple points along innate and adaptive immune signaling. The core mechanistic pathways documented in peer-reviewed literature are summarized below.

1. Toll-Like Receptor Signaling and Dendritic Cell Activation

The most mechanistically specific work on Thymosin Alpha-1 identifies Toll-like receptor (TLR) signaling as a primary pathway. A 2004 study by Romani et al. in Blood, investigating Tα1’s antifungal immune-resistance activity, found that thymosin alpha-1 induces functional maturation and interleukin-12 production by dendritic cells through the p38 MAPK/NF-κB-dependent pathway, acting via the MyD88-dependent signaling pathway involving distinct Toll-like receptors; in vivo, it activated Th1-dependent antifungal immunity, accelerated myeloid cell recovery, and protected highly susceptible transplant-recipient mice from aspergillosis (PMID: 14982877).

The TLR specificity was further refined in a 2007 study by Bozza et al. in International Immunology, which demonstrated that thymosin alpha-1 protected susceptible and resistant mice from murine cytomegalovirus infection by activating plasmacytoid dendritic cells via the TLR9/MyD88-dependent viral recognition pathway, leading to activation of IFN regulatory factor 7 and promotion of the IFN-α/IFN-γ effector pathway (PMID: 17804687). Together, these two studies document Tα1’s engagement of both myeloid DCs (via TLR2 and related pathways) and plasmacytoid DCs (via TLR9), providing a mechanistic framework for its broad immunostimulatory profile across pathogen classes.

2. T-Cell Maturation and Th1 Cytokine Polarization

The original biological rationale for thymosin research was the role of the thymus in T-cell development. A comprehensive 2016 review by King and Tuthill in Vitamins and Hormones synthesizes the mechanistic literature: Tα1 has a pleiotropic mechanism of action affecting multiple immune cell subsets involved in immune suppression; it acts through Toll-like receptors in both myeloid and plasmacytoid dendritic cells, leading to activation and stimulation of signaling pathways and initiation of production of immune-related cytokines; due to these immunostimulating effects, the compound has been studied for utility in immune suppression related to aging, infection, and cancer (PMID: 27450734).

At the T-cell level, the documented effects include stimulation of T-helper cell differentiation, upregulation of Th1 cytokines (interferon-gamma, interleukin-2), and augmentation of natural killer cell-mediated cytotoxicity, as summarized in the 2004 review by Chien and Liaw in Expert Review of Anti-Infective Therapy, which noted that in vitro studies have shown that Tα1 can influence T-cell production and maturation, stimulate production of Th1 cytokines such as interferon-gamma and interleukin-2, and activate natural killer cell-mediated cytotoxicity (PMID: 15482167).

What Does the Clinical Research Show? An Evidence-Tiered Review

Thymosin Alpha-1 has one of the larger published human clinical trial datasets of any compound in the thymic peptide category. The following summarizes each major clinical research area with primary source citations, ordered from strongest to least complete evidence as of 2026.

Chronic Hepatitis B, Randomized Controlled Trial Data

Hepatitis B is the indication with the deepest clinical evidence base for Tα1. A 2001 review by Ancell, Phipps, and Young in the American Journal of Health-System Pharmacy, a comprehensive summary of the trial record at that time, documents that in four randomized and controlled clinical trials enrolling 195 patients with chronic hepatitis B, one randomized controlled trial found HBV DNA clearance in 40.6% and 25.6% of patients treated with Tα1 for 6 and 12 months respectively, compared with 9.4% of untreated controls; an open-label trial found HBV DNA clearance in 53% of patients at six months (PMID: 11381492). The review also characterized the adverse effect profile as favorable, primarily local injection-site irritation, across the trials examined.

A 2015 editorial by Wu, Jia, and You in Expert Opinion on Biological Therapy, reviewing studies through the entecavir-combination era, confirmed that Tα1 monotherapy is effective in suppressing viral replication compared with untreated controls or conventional interferon in chronic hepatitis B, with most combination therapy studies of Tα1 plus lamivudine or IFN-α showing better effects on HBV DNA suppression and HBeAg seroconversion, and clinical studies of Tα1 combined with entecavir for HBV-cirrhosis ongoing at time of publication (PMID: 25640173).

Chronic Hepatitis C, Mixed Results

The hepatitis C evidence is more nuanced. According to a 2010 review by Ciancio and Rizzetto in Annals of the New York Academy of Sciences, a large Phase III randomized European study in HCV patients who were non-responders to PEG-interferon with ribavirin demonstrated that thymalfasin did not improve the rate of sustained virologic responses, but in patients who completed therapy, thymalfasin significantly diminished the relapse rate; smaller combination studies had previously suggested improved ALT normalization rates (71% versus 35% for combination versus IFN-α alone) and HCV RNA clearance (65% versus 29%) (PMID: 20536462). The mixed hepatitis C data illustrates the difficulty of generalizing immunomodulator effects across heterogeneous patient populations, a consistent theme in the Tα1 clinical literature.

Sepsis, Emerging Clinical Evidence

Sepsis represents a more recent clinical research context for Tα1, grounded in its documented ability to restore immune function in immunosuppressed states. A 2018 review by Pei, Guan, and Wu in Expert Opinion on Biological Therapy summarizes the clinical sepsis literature: in previous studies, single or combined treatment with Tα1 reduced the mortality rate of sepsis, improved the expression of HLA-DR on monocytes (a marker of restored immune function), and diminished the incidence of secondary infection; the authors note, however, that sepsis is a heterogeneous clinical syndrome and present studies cannot focus specifically on immunosuppressive individuals, suggesting that future trials selecting septic patients with immunosuppression would more clearly reveal Tα1’s efficacy (PMID: 30063866).

Cancer Adjuvant and COVID-19 Research Contexts

Tα1’s documented ability to restore immune function in immunosuppressed individuals has driven investigation as a cancer adjuvant and, more recently, as a potential prophylactic approach in high-risk populations during respiratory infection outbreaks. A 2021 paper by Bersanelli et al. in Future Oncology described the rationale for the PROTHYMOS study, a Phase II randomized trial evaluating Tα1 as prophylaxis for severe COVID-19 in cancer patients undergoing active treatment, stating that the immune stimulating properties of Tα1 provide a rationale for prophylactic use in this frail population, with the hypothesis that an effective prophylactic approach would have immediate clinical relevance given the lack of curative options at time of writing (PMID: 33538178).

The broadest synthesis of the clinical safety and efficacy record to date is a 2024 narrative review by Dinetz and Lee in Alternative Therapies in Health and Medicine, examining over 30 trials across more than 11, 000 human subjects. The review found that Tα1 has demonstrated consistent evidence of safety and tolerability across clinical trials in COVID-19, infectious diseases, autoimmune disorders, and cancer; the authors characterize the compound as a well-tolerated immune modulator and note that the 2023 FDA restriction on compounding appears to conflict with the body of existing trial evidence (PMID: 38308608). Note: this review was published in a journal with a less rigorous peer-review process than specialty clinical journals; researchers should weigh it accordingly and consult primary trial publications for specific indication-level evidence.

What Is Thymosin Alpha-1’s Evidence Tier? An Honest Assessment

Thymosin Alpha-1 occupies a distinct position in the research peptide landscape because of its substantial human clinical trial record, a characteristic that separates it from most compounds in this category, where Tier 2 (animal models only) is the ceiling. The following table documents the evidence landscape as of 2026.

The critical nuance to state accurately: Thymosin Alpha-1 is a genuinely atypical compound in this research landscape because it has cleared Phase III human trials for at least one indication (hepatitis B) and is a licensed pharmaceutical in dozens of countries. However, it is equally important to note that (a) those approvals do not apply to the U.S. context, where FDA restrictions on compounding reflect current regulatory status; (b) the evidence is indication-specific, results in hepatitis B do not generalize to other hypothetical uses without independent clinical trial support; and (c) “approved elsewhere” is a regulatory fact, not an endorsement of any particular research use. This article is a reference document, not a protocol guide.

What Is Thymosin Alpha-1’s Regulatory Status?

International Approvals (Zadaxin / Thymalfasin)

Thymalfasin under the trade name Zadaxin received pharmaceutical approvals in multiple countries for the treatment of chronic HBV and HCV infection beginning in the 1990s. Documented approval countries include China, the Philippines, Argentina, Peru, Singapore, Thailand, Mexico, Venezuela, Malta, Sri Lanka, Brunei, India, Laos, South Korea (as an influenza vaccine adjuvant and HBV/HCV treatment), and others, as documented in public regulatory filings and the 2002 Billich review cited above. Researchers should consult current regulatory authority databases directly for up-to-date status in any given jurisdiction.

FDA (United States)

Thymosin Alpha-1 has never received FDA approval for any therapeutic indication in the United States, despite completing Phase III trials for hepatitis C in the U.S. market. In 2023, the FDA placed thymalfasin on its list of bulk drug substances that may not be used in compounding under Section 503A, alongside 21 other peptide compounds. This restriction means it cannot be legally compounded and dispensed by U.S. pharmacies. Researchers should consult current FDA guidance directly for the most up-to-date classification and any IND or trial-related exemptions.

WADA (World Anti-Doping Agency)

Thymosin Alpha-1 is not individually named in the WADA Prohibited List’s specific compound enumerations as of the 2025–2026 lists. However, WADA’s Prohibited List uses broad category language under Section S4 (Hormone and Metabolic Modulators) and Section S0 (Non-Approved Substances, covering any pharmacological substance not approved by a regulatory authority for human therapeutic use in any jurisdiction). Athletes competing under WADA-compliant anti-doping programs should consult the current WADA Prohibited List, their national anti-doping organization, or use the WADA Global DRO tool to confirm status before any potential use. The research framing of this article does not apply to competitive sports contexts.

How Does Thymosin Alpha-1 Differ from Other Thymosin-Named Peptides?

The naming convention causes significant confusion. “Thymosin” describes a broad class of biologically active peptides originally isolated from thymic extracts, they are not a structurally or functionally unified family. The major thymosin-named peptides in research literature differ fundamentally:

• Thymosin Alpha-1 (Tα1 / thymalfasin), 28 amino acids; thymic origin; TLR/DC/Th1 immune modulator; clinical trials in infectious disease and cancer; approved as Zadaxin in 35+ countries.
• Thymosin Beta-4 (Tβ4) / TB-500, 43 amino acids (full protein) or synthetic fragment; ubiquitous in mammalian cells; G-actin sequestration mechanism; tissue repair research context; detailed in the TB-500 compound profile.
• Thymosin Fraction 5, the crude bovine thymus extract from which Tα1 was originally isolated; a mixture of peptides, not a single defined compound.

These distinctions matter for literature interpretation: studies on Tβ4 do not support claims about Tα1 and vice versa. The shared “thymosin” label is historical nomenclature, not a functional classifier.

Frequently Asked Questions About Thymosin Alpha-1

What is Thymosin Alpha-1 and is it FDA approved?

Thymosin Alpha-1 (thymalfasin, trade name Zadaxin) is a synthetic 28-amino acid peptide originally isolated from thymic tissue, studied primarily as an immune modulator. It is approved as a prescription drug in more than 35 countries for hepatitis B and C treatment. It is not approved by the U.S. FDA, and in 2023 the FDA specifically restricted its compounding. In the United States it is a research compound. Where approved internationally, it is a regulated pharmaceutical used under medical supervision.

What does the Thymosin Alpha-1 research actually show?

Based on articles retrieved from PubMed, the research record includes: (1) multiple published RCTs in chronic hepatitis B showing statistically significant HBV DNA clearance vs. controls; (2) Phase III hepatitis C data showing mixed results on sustained virologic response but reduced relapse in completers; (3) clinical sepsis studies showing reduced mortality and secondary infection rates; (4) mechanistic studies documenting TLR2/TLR9-driven dendritic cell activation and Th1 polarization; and (5) ongoing investigation in cancer adjuvant and infectious disease prevention contexts. This is a more robust human clinical data set than most research compounds in this category carry.

What is Thymosin Alpha-1’s WADA status?

Thymosin Alpha-1 is not individually listed by name in current WADA Prohibited List enumerations. However, the S0 category covers non-FDA-approved pharmacological substances, which may capture Tα1 in U.S.-adjacent anti-doping contexts. Athletes should consult the WADA Global DRO tool and their national anti-doping organization directly, this article does not constitute anti-doping guidance.

How does Thymosin Alpha-1 differ from TB-500 (Thymosin beta-4)?

They are unrelated despite the shared name. Thymosin Alpha-1 is a 28-aa thymic immune modulator (TLR/Th1 pathways; hepatitis and sepsis clinical trial record). TB-500 is a synthetic fragment of the 43-aa Thymosin beta-4, which acts primarily through G-actin sequestration and cell migration in tissue-repair contexts. The two peptides share historical thymus-extract origins but differ in sequence, structure, receptor biology, and clinical history. See the full TB-500 compound profile and the tissue repair and recovery cluster overview for comparison.

Research use only. Not intended for human use. Not FDA approved in the United States. This article documents published scientific literature for educational and reference purposes and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. The international drug approval status of thymalfasin (Zadaxin) is cited as a documented regulatory fact, not as an endorsement of any use of this compound outside licensed medical supervision. All citations link to primary sources, read them in full. Must be 21+.

TL;DR: MK-677 (ibutamoren mesylate) is an orally active, non-peptide small molecule that acts as a potent agonist at the ghrelin receptor (GHS-R1a), stimulating pulsatile GH and IGF-1 release. Unlike the peptidic GHRPs and GHRH analogs in the same research cluster, it is a synthetic spiropiperidine compound, not a peptide. Multiple human randomized controlled trials have documented measurable GH/IGF-1 elevation; the most notable 2-year study showed increased fat-free mass in older adults without serious adverse effects, though insulin sensitivity decreased. MK-677 is not FDA approved for any human use and is prohibited by WADA under Section S2.

Research-Use Disclaimer: This article is for educational and research reference purposes only. MK-677 is a research compound, not approved by the FDA for human use. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published clinical and preclinical research. For adults 21+ with a research interest only.

What Is MK-677? Definition, Structure, and Classification

MK-677, also designated MK-0677 in clinical trial literature and sold under the research name ibutamoren mesylate, is a synthetic, orally active small molecule developed at Merck Research Laboratories. Its chemical structure is an indoline-derived spiropiperidine compound. This is a critical distinction: MK-677 is not a peptide. It does not consist of an amino acid chain and is not structurally related to the peptidic growth hormone-releasing peptides (GHRPs) such as GHRP-6, GHRP-2, or ipamorelin, nor to the GHRH-analog class.

MK-677 is most accurately classified as a ghrelin receptor agonist or ghrelin mimetic, a non-peptide compound designed to activate the growth hormone secretagogue receptor subtype 1a (GHS-R1a), the same receptor through which ghrelin, the endogenous gut-derived peptide hormone, exerts its GH-releasing effects. In the research literature, MK-677 is frequently grouped alongside GH secretagogues, compounds that stimulate endogenous GH release, because its pharmacological endpoint is functionally identical to that of peptidic GHRPs, even though its molecular structure differs substantially.

How Does MK-677 Work? The Ghrelin Receptor Mechanism

MK-677 stimulates GH release by binding as a full agonist to GHS-R1a, a G protein-coupled receptor (GPCR) expressed primarily on somatotroph cells in the anterior pituitary and on hypothalamic neurons. GHS-R1a activation triggers two parallel stimulatory pathways: direct pituitary stimulation of GH release from somatotrophs, and hypothalamic stimulation of endogenous growth hormone-releasing hormone (GHRH) secretion. These two signals act synergistically to produce a robust, pulsatile GH secretory burst.

What Does GHS-R1a Agonism Produce in Research Subjects?

In research subjects across multiple published trials, oral MK-677 at 25 mg/day consistently produced acute GH pulses followed by sustained elevation of circulating IGF-1. The mechanistic basis, GHS-R1a acting as the physiologically relevant ghrelin receptor, was confirmed in a 2004 study by Sun et al. published in Proceedings of the National Academy of Sciences, which used GHS-R1a knockout mice to demonstrate that both ghrelin-stimulated GH release and appetite stimulation were entirely absent in Ghsr-null animals, confirming GHS-R1a as the biologically required receptor for ghrelin mimetic activity (PMID 15070777). MK-677 was the compound used to expression-clone GHS-R1a in foundational receptor pharmacology work, making it a central reference tool in GH secretagogue research.

A 2004 review by Smith et al. at Baylor College of Medicine in Best Practice & Research: Clinical Endocrinology & Metabolism summarized the pharmacological rationale: chronic administration of MK-677 reverses the age-related decline in GH pulse amplitude and restores IGF-1 levels to profiles typical of young adults, findings that established the GHS compound class as a candidate tool for investigating age-related decline of the GH/IGF-1 axis (PMID 15261841).

How MK-677 Differs Mechanistically from Peptidic Secretagogues

Because MK-677 is a small molecule rather than a peptide, it is orally bioavailable, a pharmacokinetic property that peptidic GHRPs do not share due to protease degradation in the GI tract. This oral activity was a primary driver of its development and differentiates it practically from ipamorelin and the GHRH-analog class. The compound acts at the same receptor as the peptidic GHRPs but through a distinct binding mode; its extended duration of action compared to short-acting peptide secretagogues has been noted in multiple trials and is attributed to its small-molecule stability.

What Does the Research on MK-677 Show? Evidence by Tier

MK-677 is unusual among GH-axis research compounds in having a published human RCT base spanning multiple indications and subject populations. The following summarizes the key published findings from PubMed-indexed studies.

Human RCT: Reversal of Diet-Induced Nitrogen Catabolism

A 1998 double-blind, placebo-controlled crossover RCT by Murphy et al. at Merck Research Laboratories, published in the Journal of Clinical Endocrinology & Metabolism, enrolled eight healthy male volunteers in a caloric restriction protocol. During the MK-677 treatment week, mean daily nitrogen balance in subjects receiving oral MK-677 25 mg was +0.31 g/day versus −1.48 g/day in the placebo group (P < 0.01), reversing diet-induced nitrogen wasting (PMID 9467534). MK-677 also produced significant IGF-1 elevation (mean 264 ng/mL on active treatment versus 188 ng/mL on placebo, P < 0.01) and increased IGFBP-3. Neither serum cortisol nor prolactin responses were significantly elevated compared to placebo after 7 days of dosing, a selectivity profile that distinguishes it from older GHRP compounds.

Human RCT: Sleep Architecture in Young and Older Adults

A 1997 controlled trial by Copinschi et al. at the Free University of Brussels, published in Neuroendocrinology, investigated MK-677’s effects on polysomnographic sleep measures in both young adults (ages 18–30) and older subjects (ages 65–71). High-dose MK-677 (25 mg) increased Stage IV sleep duration by approximately 50% and REM sleep by more than 20% relative to placebo in young subjects (P < 0.05); in older adults, REM sleep increased nearly 50% and REM latency decreased, with a reduction in sleep deviations from normal (PMID 9349662). The authors proposed that MK-677 may simultaneously improve sleep quality and address the relative hyposomatotropism of aging, a hypothesis that has informed subsequent GHS research.

Human RCT: Bone Turnover Markers in Elderly Adults

A 1999 RCT by Murphy et al. (Merck Research Laboratories), published in the Journal of Bone and Mineral Research, pooled data across 187 elderly adults (65+) enrolled in three randomized, double-blind, placebo-controlled studies of 2–9 weeks duration. Treatment with MK-677 25 mg increased serum IGF-1 by 55–94% across study arms and elevated markers of both bone formation (osteocalcin +29.4%, bone-specific alkaline phosphatase +10.4%) and bone resorption (urinary N-telopeptide +22.6%) in functionally impaired elderly subjects (PMID 10404019). The correlation between IGF-1 change and osteocalcin change (r = 0.37, P < 0.01) indicated IGF-1-mediated bone turnover stimulation.

Human RCT: Bone Markers in Obese Young Males

A 1998 randomized, double-blind, parallel, placebo-controlled study by Svensson et al. at the Sahlgrenska University Hospital, published in the Journal of Bone and Mineral Research, enrolled 24 healthy obese males (ages 19–49) receiving 25 mg MK-677 or placebo daily for 8 weeks. MK-677 increased markers of bone formation (procollagen type I carboxy-terminal propeptide +23%, procollagen III peptide +28% at 2 weeks; osteocalcin +15% at 8 weeks) and bone resorption, alongside significant IGF-1 and IGFBP-5 elevation (PMID 9661080). The study called for longer-term investigation of whether sustained MK-677 treatment increases bone mass.

Human RCT: Two-Year Body Composition Study in Healthy Older Adults

The most extensively cited MK-677 study is a 2-year, double-blind, randomized, placebo-controlled trial by Nass et al. at the University of Virginia, published in the Annals of Internal Medicine (2008). Sixty-five healthy adults aged 60–81 received oral MK-677 25 mg or placebo daily. Daily MK-677 administration significantly increased GH and IGF-1 to levels typical of healthy young adults; fat-free mass declined in the placebo group but increased by a mean of 1.1 kg in the MK-677 group (versus −0.5 kg in placebo; P < 0.001); body cell mass, as reflected by intracellular water, increased in the MK-677 group versus placebo (P = 0.021) (PMID 18981485). No significant differences in abdominal visceral fat were observed. Adverse effects included a transient increase in appetite, mild lower-extremity edema, muscle pain, an increase in fasting blood glucose of ~5 mg/dL (P = 0.015), and a decrease in insulin sensitivity. Cortisol levels increased by a mean of 47 nmol/L in MK-677 recipients. The increase in fat-free mass did not translate into improvements in isokinetic strength or functional measures, an important limitation the authors emphasized.

Human RCT: Alzheimer’s Disease, Target Engagement Without Efficacy

A landmark Merck-sponsored multicenter RCT by Sevigny et al. (2008), published in Neurology, randomized 563 patients with mild to moderate Alzheimer’s disease to MK-677 25 mg or placebo daily for 12 months. The trial was designed to test whether IGF-1 elevation could slow AD progression. MK-677 produced a 60.1% increase in serum IGF-1 at 6 weeks and 72.9% at 12 months, confirming target engagement, but had no significant effect on ADAS-Cog, CIBIC-plus, ADCS-ADL, or CDR-sob scores (PMID 19015485). This trial is methodologically significant for the MK-677 research literature: it establishes that MK-677’s IGF-1 elevation is robust and reproducible at scale, while simultaneously demonstrating that IGF-1 elevation alone is insufficient to modify Alzheimer’s disease progression.

What Is MK-677’s Evidence Tier? An Honest Assessment

MK-677 occupies an unusual position in the GH secretagogue research space: it has more published human RCT data than most compounds in this cluster, yet it remains unapproved for any indication. The table below summarizes the evidence landscape:

The critical limitation to state plainly: GH and IGF-1 elevation are pharmacological endpoints, not functional or clinical outcomes. The published 2-year RCT demonstrated increased fat-free mass but explicitly found no improvement in isokinetic strength or functional measures in older adults. The Alzheimer’s trial confirmed IGF-1 target engagement at scale but found no clinical benefit. Researchers and science communicators should not conflate documented GH/IGF-1 elevation with demonstrated improvements in performance, longevity, or disease-relevant outcomes, the evidence does not support that equivalence.

Additionally, MK-677’s adverse effect profile, specifically its effect on fasting blood glucose and insulin sensitivity, is documented across multiple trials and warrants careful consideration in research design. Subjects in the Nass et al. (2008) two-year trial showed a mean fasting glucose increase of 5 mg/dL and measurable reduction in insulin sensitivity, findings that are consistent with GH’s known insulin-antagonizing effects.

What Is MK-677’s Regulatory Status?

FDA (United States)

MK-677 (ibutamoren) is not approved by the U.S. Food and Drug Administration as a drug, biologic, or dietary supplement ingredient. Merck conducted multiple clinical trials of MK-677 through the 1990s and 2000s; the compound did not advance to FDA approval for any indication. It is classified as a research compound. Researchers should consult current FDA guidance directly for import, handling, and permissible research use.

WADA (World Anti-Doping Agency)

MK-677 is prohibited under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics on the WADA Prohibited List. Section S2 encompasses all growth hormone-releasing substances, including ghrelin mimetics and non-peptide GHS-R1a agonists, regardless of their molecular classification as peptide or small molecule. The prohibition applies both in-competition and out-of-competition for all athletes subject to WADA rules. Athletes governed by anti-doping codes should consult the current published Prohibited List directly.

Frequently Asked Questions About MK-677 (Ibutamoren)

Is MK-677 (ibutamoren) a peptide?

No. MK-677 is not a peptide. It is a synthetic small-molecule ghrelin-receptor agonist, an indoline-derived spiropiperidine compound that mimics ghrelin’s action at GHS-R1a without being an amino acid chain. It is often discussed alongside peptidic GH secretagogues such as ipamorelin and CJC-1295 because it targets the same receptor and produces the same downstream GH/IGF-1 effects, but its chemical classification is distinct. Describing MK-677 as a peptide is a factual error common in non-scientific sources.

What does the human research on MK-677 actually show?

Published human RCTs document consistent GH and IGF-1 elevation at 25 mg/day, along with increased fat-free mass in older adults and reversal of diet-induced nitrogen wasting in healthy volunteers. The landmark 2-year Nass et al. (2008) trial, the most comprehensive published study, found statistically significant increases in fat-free mass and body cell mass versus placebo, but no improvements in functional strength. Documented adverse effects include reduced insulin sensitivity, fasting glucose elevation, transient edema, increased appetite, and cortisol elevation.

Is MK-677 FDA approved?

No. MK-677 has been studied in multiple human clinical trials but has not received FDA approval for any indication. It is not available as an approved prescription drug or dietary supplement in the United States and is classified as a research compound.

Is MK-677 on the WADA Prohibited List?

Yes. WADA prohibits MK-677 under Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics, which covers all GH-releasing substances and ghrelin mimetics. The prohibition applies both in-competition and out-of-competition for athletes subject to WADA rules, regardless of whether a substance is peptide-derived or a small molecule.

For educational and research reference purposes only. Not medical advice. Not for human use.